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Resumo 
 
A terapia génica pode ser definida como a introdução de material genético numa célula 
para a complementação ou silenciamento de genes defeituosos, podendo ser aplicada 
no tratamento de doenças, tais como cancro, imunodeficiências, distrofia muscular e 
fibrose cística. Os vetores não virais baseados em polímeros catiónicos – poliplexos - 
apresentam-se como uma das mais promissoras tecnologias para este fim, devido à 
reduzida imunogenicidade e elevada flexibilidade de funcionalização.  
Este trabalho teve como objetivo genérico a produção e caracterização de poliplexos 
(complexos de ácidos nucleicos com policatiões) com capacidade de degradação em 
contacto com o ambiente oxido-redutor do citosol celular – poliplexos biorredutíveis. 
Como objetivos mais específicos, pretendeu-se estabelecer uma melhor compreensão 
sobre o efeito do processo de mistura sobre a estrutura dos poliplexos, por recurso à 
técnica de microfluídica, a qual permite um melhor controlo sob o processo de mistura 
dos diferentes componentes. 
No decorrer do projeto, o sistema DNA plasmídico/poli-L-lisina (PLL) foi produzido e 
caracterizado em solução e em ambiente microfluídico, servindo como sistema de 
referência, enquanto que o sistema DNA plasmídico/poli-L-lisina biorredutível (bPLL) foi 
produzido e caracterizado em solução.  
Estes sistemas de poliplexos foram preparados em meio aquoso, numa vasta gama de 
razão de carga polímero:DNA (+/-). A estabilidade destes complexos foi estudada em 
tampão fisiológico e em tampão a diferente força iónica. Todos os complexos 
preparados foram estruturalmente caracterizados por determinação de tamanho e 
potencial zeta. Os dois sistemas, pDNA/PLL e pDNA/bPLL, demonstraram possuir 
características idênticas em meio aquoso, mas estabilidades em tampão bastante 
distintas entre si, diferenciando-se de forma significativa na presença de elevada força 
iónica. 
Este trabalho visa assim contribuir para uma melhor compreensão sobre a influência do 
processo de mistura sobre a estrutura final do poliplexo, assim como para um melhor 
conhecimento sobre o efeito que a propriedade de biorredutibilidade tem nas 
propriedades físico-químicas dos complexos policatião/DNA. 
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Abstract 
 
Gene therapy may be defined as the introduction of genetic material into a cell for the 
complementation or silencing of defective genes and may be applied in the treatment of 
diseases such as cancer, immunodeficiencies, cystic fibrosis and muscular distrophy. 
Non-viral vectors based on cationic polymers - polyplexes - are one of the most 
promising technologies for this purpose due to the low immunogenicity and high flexibility 
of functionalization. 
In this work, our general goal was the preparation an and characterization of bioreducible 
polyplexes that degrade in contact with the redox environment of the cellular cytosol. As 
more specific objectives, we intended to establish a better understanding of the effect of 
the mixing process on the structure of the polyplexes, thus using the microfluidic 
technique which allows better control over the mixing process of the different 
components. 
During the project, the plasmid DNA/poly-L-lysine (PLL) system was produced and 
characterized in bulk and microfluidic environment, serving as a reference system, 
whereas the plasmid DNA/bioreducible poly-L-lysine (bPLL) system was produced and 
characterized in bulk. 
These polyplex systems were prepared in water over a wide range of polymer:DNA (+/-
) charge ratios. The stability of these complexes was studied in physiological buffer, and 
also in buffer with different ionic strengths. All complexes prepared were structurally 
characterized by their size and zeta potential. The two systems, pDNA/PLL and 
pDNA/bPLL, have shown similar characteristics in water, but rather different stabilities in 
buffer, varying significantly in the presence of high ionic strength. 
This work is a contribution to a better understanding of the influence of the mixing 
process on the final structure of the polyplex, providing information about the effect that 
the bioreducibility property has on the physicochemical properties of the complex.  
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1. Introduction  
 
Since the understanding of the role of nucleic acids in encoding and translating genetic 
information into biological function1-2, the increasing biochemical and biophysical 
knowledge gained also opened new opportunities for therapeutic interventions at the 
molecular level. Variations at the nucleic acid codification may directly cause illnesses 
or be associated with disease development. Therefore, the introduction of artificial 
therapeutic nucleic acids into the cell matrix should be able to lessen the severity and 
even cure diseases. This strategy clearly has other potential applications, including in 
cardiovascular3-4, inflammatory5 and infectious diseases6-9, cancer10 as well as organ 
transplant11. The delivery of the various therapeutic nucleic acids to their required cellular 
site of action has appeared as a major problem that delayed medical progress. 
Complexation of nucleic acid with polymeric carriers into polyplex nanoparticles is one 
possible approach to facilitate the delivery and hence overcome some of the problems. 
 
1.1 Gene therapy  
 
Research efforts have been focused on designing effective carrier vectors that compact 
and protect nucleic acids for gene therapy, since free oligonucleotides and DNA are 
rapidly degraded by serum nucleases in the blood if injected intravenously12. Initial 
research concentrated on using viral carriers to transport the genetic material into the 
cell. Viruses have been optimized by nature for nucleic acid transfer into host cells and 
represent the most efficient delivery vehicles. Despite their high transfer efficiency13, viral 
carriers present substantial limitations, such as immunogenicity, limited cargo capacity, 
restricted cell tropism, or sophisticated analytics and production14.  
Non-viral vector systems, including cationic lipids15-17, polymers18-19, dendrimers20, and 
peptides21, all offer potential routes for DNA complexation for systemic delivery. 
However, unlike viral analogues that have evolved significantly to overcome cellular 
barriers and immune defense mechanisms, non-viral gene carriers consistently exhibit 
low transfection efficiency as they are blocked by many intra- and extracellular barriers. 
However, these systems are very attractive to this type of therapy, due to their capacity 
to self-assembly and high level functionalization22. Therefore, this type of carrier needs 
to present properties such as: stability in the extracellular environment, interaction with 
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target cell surface and cell uptake, release from endosomal vesicles and finally DNA 
unpacking23-25 (figure 1). 
 
Fig. 1 – Schematics of the polyplex/lipoplex formation and latent cellular barriers. Adapted from26. 
  
1.1.1 DNA Complexation 
 
Cellular uptake of free DNA via plasma membrane permeation is hindered by the size 
and negative charge of the DNA. While several studies have shown that free DNA can 
be introduced into cells through electroporation, gene gun, or direct injection into target 
tissue, the clinical relevance of these methods is limited25. Systemic circulation of free 
DNA is hampered by nuclease degradation. 
At the cell level, mandatory compaction of the genome is obtained by complexation with 
agents such as multivalent ions, cationic surfactants, cationic polymers,  or small 
polycationic proteins combined with monovalent and divalent ions into large 
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nucleoprotein complexes27. It has been reported that only 50% of all the negative charge 
of DNA is neutralized by polycation proteins, such as histones, while the other 50% is 
neutralized by positive ions28. It is also important to note that the transition from elongated 
coil to a condensed state only occurs when 89-90% of the negative charges are 
neutralized by positive counterions29. The understanding of the genome compaction lead 
to the first studies of DNA complexation using polycationic agents in the 1970s. These 
agents range from multivalent ions, cationic surfactants and cationic polymers30-33.  
The properties of the media where the complexation between the polymer and DNA 
occurs play an important role in the final structure of the formed particle (polyplex). The 
interactions between the two cosolutes are essentially electrostatic. Each charged 
molecule has a diffuse electrical double layer with some strongly bond counterions; upon 
release of these counterions due to complexation, there is a strong gain of entropy.  
Some strategies can be used to alter complex formation and stability, including (i) 
addition of monovalent salt, and (ii) pH changes. Regarding effect (i), the addition of 
small electrolytes can aid the self-assembly of polyplexes by shielding the intramolecular 
charge repulsions, thus increasing the flexibility of the polymers and their ability to self-
assemble34. On the other hand, high salt concentrations can lead to strong electrostatic 
screening between polyplexes leading to swelling and subsequent aggregation of 
swollen complexes. Also, the presence of high salt concentration before complexation 
decreases the entropic gain due to counterion release, thus decreasing the nucleation 
rate. Regarding effect (ii), polymers can be classified as either weak or strong whether 
they undergo partial or full ionization at physiological pH. For example PEI – 
polyethylenimine – is a weak polyelectrolyte with a pKa ≈ 7 35, while PLL – poly-L-lysine 
– is a strong polyelectrolyte due to NH2 groups with a pKa ≈ 10 36. As a result, and 
contrary to strong polyelectrolytes, the charge density of weak polyions will strongly 
depend on the pH found in different tissues and organelles. The variation within the pH 
range can lead to significant changes in polyelectrolyte binding and stability depending 
on the loss or gain of valency, i.e. charges per molecule37.  
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1.1.2 Extra and Intracellular Delivery 
 
The polycation should be able to confer protection to nucleic acids, and be strong enough 
to remain complexed in the presence of physiological competitors, such as serum 
proteins. An aspect that is common to almost every study is that polyplexes with a charge 
ratio (positive charge/negative charge) less or equal to 1 exhibit a poor gene transfer, 
while higher charge ratios yield high efficiency21, 38. Consequently, efficient polyplexes 
are formed when the number of positive charges overcomes the number of negative 
charges, and the physicochemical properties may be controlled by this charge ratio.  
The polyplex size is a very important parameter for systemic administration, with a great 
impact in biodistribution and pharmacokinetics25. Nanoparticles with a hydrodynamic 
diameter below 6 nm are rapidly removed by the kidneys. On the other hand, particles 
sized up to 400 nm may facilitate accumulation on highly vascularized tumors39-41. Thus, 
the success of gene delivery is dependent of both size and surface charge, since these 
properties influence the circulation time, cellular binding and uptake, and intracellular 
trafficking of polyplexes42. 
The importance of polyplex stability in blood and other fluids is also a critical issue to 
regard. This stability is threatened by electrolytes, proteins, or cellular surfaces which 
may cause complex distabilization43. Some complications could arise from this, such as 
loss of delivery efficacy, binding of positively charged polyplexes with serum complement 
protein, activation of the innate immune system44 or self-aggregation into larger 
microstructures45. A possible counteracting measure is to introduce elements within the 
polymer backbone to shield it against undesired interactions with the bioenvironment; 
however, cell binding and uptake may be affected.  
The first barrier to the entrance of the polyplex in the cell is the cell membrane. The entry 
across the cell membrane does not occur passively, and so this presents the first 
challenge relating to intracellular delivery. Unless there is any chemical messenger on 
the surface of the polyplex, the binding typically occurs by particle/membrane 
electrostatic interaction46. The direct transfer to cytosol by protein channels and carriers 
only works for small molecules. It is also possible for some enveloped viruses47, which 
bind and fuse their membrane with the target cell membrane releasing directly their 
payload. Nonenveloped viruses and polypeptides use an alternative two-step entry 
mechanism: first, engulfment into intracellular vesicles; second, escape from the vesicles 
to the cytosol. Other non-lipid particles are also subject to this same process, although 
the endosomal escape is quite inefficient. Many endocytosis processes exist48. 
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Transcytosis, trafficking into Golgi organelles and endoplasmic reticulum, or maturation 
into lysosomes that enzymatically degrade their content, are some of the fates referred 
previously. Clearly, the latter fate is to be avoided for prolific delivery of nucleic acids.  
The next stage of the polyplex life cycle is the cytoplasm diffusion and vector 
dissociation, which also represents a problem. Several strategies have been studied to 
facilitate the disassembly of polyplexes by taking advantage of the different conditions 
experimented during the cellular trafficking, such as different pH and redox potential 
gradient. Bioreducible polymers containing disulfide bonds are extracellularly stable 
providing stability to the complex, while the reducing environment of the intracellular 
medium leads to polymer breakdown and acid nucleic release49. Studies involving 
bioreducible polymers show an increase in gene transfection when compared to 
nonreducible ones50-51. Gene-encoding plasmid DNAs have their destination in the 
nucleus, whereas mRNA or siRNA targets are in the cytosol, where migration is size-
dependent52-53. For efficient delivery, the DNA must be transported along microtubes 
toward the nuclear envelope to be imported into nucleus by active mechanisms or 
alternative pathways, and be retained there in active form. Improved delivery into the 
nucleus by active transport domains, in particular small peptides, has been reported in 
many studies54-55.  
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1.2 Polymer-based Carriers  
 
Polymers are natural candidates for the transport of therapeutic nucleic acid, because 
they contain the necessary features to fulfill the extracellular and intracellular 
requirements. They can bind, condense, protect and release nucleic acids. In addition, 
they can bind to cell surfaces, trigger intracellular uptake, and mediate endosomal 
membrane destabilization required for cytosolic release. They cannot comply these 
actions in the desired time sequence required. Thus, within the bioenvironment, they are 
subjected to many secondary interactions that hinder activity and increase cytotoxicity25, 
56-57.   
The first batch of polymers ever studied, 
with application in gene delivery, were 
biomolecules already known, such as 
DEAE-dextran, traced back to 196558-59, or 
peptides such as polylysine and 
polyornithine. In a study made in 1975 by 
Farber, spermine , polyornithine, DEAE-
dextran, polylysine and polyarginine, 
represented in figure 2, were evaluated for 
the transfection of exogenous mammalian 
DNA, proving that polyornithine had the 
best performance60. Early spectroscopic 
and electron microscopy studies provided a 
window into the mechanism of 
complexation of polymer/DNA. It was 
shown that polycations bind and condense nucleic acids into organized and regular 
nanostructures like rods and toroids30, 33, 61-63.  
The development of ever more efficient polyplexes went alongside the understanding of 
the mechanism of transfection. As mentioned before, polyplexes are engulfed within the 
cell membrane, penetrating the cell through vesicle formation, namely endosomes, by a 
variety of pathways64. Once in endocytic vesicles, the trapped non-viral vectors suffer a 
pH drop from natural to around 6. In this stage, called early endosome stage, two 
pathways are available: in the first path, the endosome content is externalized and, in 
the second and more frequent path, the vesicles turn into late endosomes, becoming 
more acidic. The last step involves the fusion of late endosomes with lysosomes with a 
further pH reduction to pH 4.5, through the action of degrative enzymes. Therefore, if 
Fig. 2 - Structure of polymers used in the 1975 study of 
transfection efficiency of polyplexes. (a) Spermine; (b) 
polyornithine; (c) DEAE-dextran; (d) polylysine; (e) 
polyarginine.  
(a) 
(b) 
(c) 
(d) 
(e) 
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nucleic acids are trapped in these vesicles until this stage, their degradation will occur 
and the process of gene delivery fails.   
It was discovered that by coupling the polyplexes with an antimalarial agent, chloroquine, 
the transfection would greatly increase. This strategy was first reported in 1983 by 
Luthman and Magnusson65. The effect of chloroquine66-68 is largely based on the natural 
acidification process that occurs in endosomes due to ATPase. This enzyme actively 
transports protons to reach the desired pH. ATPase generates a proton gradient with a 
pH ~ 6 in early endosomes and down to 4.5 to late endosomes and lysosomes69-70. The 
unprotonated form of this drug can diffuse across lipid membranes into the cell and in 
the acidic environment of endosomes and lysosomes, it becomes protonated and thus 
entrapped. With the continued activity of ATPase, the drug further accumulates in the 
vesicles, triggering an inflow of chloride counterions, via specific carriers, and water. This 
results in increased osmotic pressure and swelling, leading to membrane destabilization 
and rupture, releasing the vectors to the cytoplasm. The scheme of this mechanism is 
shown in figure 3. A way to improve the transfection and eliminate possible side effects 
from chloroquine and analogues, would be to incorporate this proton-sponge feature into 
the polymer71.  
Polyamides are the first group of polymers that may be used when looking for proton-
sponge features. They are only partly protonated at neutral extracellular pH and would 
still condense the DNA by electrostatic interactions, but they would increase their 
protonation and charge density within the acidic vesicle. This process should destabilize 
the polyplex-containing endosomal vesicle. The criteria would not be fulfilled by the 
already mentioned polylysine, polyarginine, or polyornithine, due to their full cationic 
state at physiological pH. This approach led to the discovery and use of polyethylemine 
(PEI) and polyamidoamines (PAAs) as very efficient carriers71.  
Recent strategies used to enhance the escape of nucleic acids from endosome are 
based on the design of new vectors regarding their buffering capacity. A widely used 
buffering moiety is the imidazole ring of histidine that is a weak base with a pKa ≈ 6, 
conferring the ability to acquire capture proton when the pH of the environment drops 
below 6. The attachment of these amino acids moieties to polymers, lipids or peptides 
has shown to enhance their transfection efficiency and often reduce their cytotoxicity72-
73.  
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1.2.1 Biodegradable Polymers 
 
Biodegradable polymers go hand in hand with biomedical applications. In particular, 
hydrolytically degradable aliphatic polyesters, polyamides, polyorthoesters and 
polycarbonates have become part of biomaterials, devices and drug delivery systems74. 
Polymers that are degradable by cleavage of the disulfide bonds represent a growing 
class of biodegradable polymers, receiving more attention since the early 2000’s, when 
they began to be explored in nucleic acids delivery75. Numerous other disulfide-
containing polymers have been extensively used in industrial applications, such as the 
vulcanized rubber76. Disulfide bonds have also been applied to drug-protein 
conjugations77.  
Due to the unique nature of the disulfide bond, which can be easily formed and cleaved, 
polymers with this feature can be applied to adaptable and self-repairing materials and 
in material design78-79. From the biodegradable polymers group, the subgroup that is 
most important for gene delivery is the disulfide-containing polycations. As discussed 
above, these polymers combined with nucleic acids form polyelectrolyte complexes that 
serve to protect the nucleic acids and transport them to the desired destination. This 
protection should be continuous through the extracellular and intracellular environment. 
Using a simplified view of the nucleic acid delivery process and the known 
compartmentalization of disulfide reducing activity in the biological environment, it has 
been hypothesized that bioreducible polycations can provide such extracellular 
Fig. 3 – Representation of the endosomal escape mechanism based on the proton-sponge properties of polymers. Red string – polymer, 
and orange string – DNA.   
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protection and selective intracellular release of nucleic acids. High disulfide reducing 
capacity in biological environment coincides with the location in which the nucleic acids 
are to be released. 
 
Biological Environment 
 
The disulfide-containing bioreducible polycations desire their utility from the complex 
system of redox processes that are involved in important biological pathways and cell 
mechanisms. The redox gradient that exist between extracellular, intracellular 
environments, and subcellular organelles provides a great route for redox stimulus-
responsive polycations in gene delivery. The redox environment present in cells is in 
dynamic equilibrium and may change depending on many factors including stage of cell 
cycle and biological status of the cell80. The most important agent responsible for the 
redox state of a cell is glutathione (GSH). This agent is the most abundant intracellular 
thiol and its concentration reaches millimolar levels inside the cell and micromolar levels 
in the blood plasma81-82. Due to its redox properties, GHS is involved is many cellular 
processes, including DNA and protein synthesis, enzyme activity, and metabolism and 
cell protection against oxidative stress83. The glutathione exists in two main states: the 
reduced and more abundant form GHS, and the oxidized state GSSG. The GSH/GSSG 
ratio is an indicator of the redox environment within the cell80.  
The most reducing environment, within the cell, is the microenvironment around the 
nucleus where the levels of GSH reach up to 20 mM compared with 1-11 mM in the 
cytosol. This happens because GSH is required for DNA synthesis and repair and to 
maintain transcription factors in reduced state84.  
 
Thiol-Disulfide Exchange Reaction  
 
Disulfide bonds and their reactions are very important for biological systems to survive. 
They help in redox homeostasis, in correct assembly of proteins, and in the metabolic 
regulation of enzymatic activity. Due to their importance, cells evolved robust 
mechanisms for the formation, cleavage, and reshuffling of disulfide bonds in proteins85. 
The mechanisms are mainly based in exchange reactions of thiol-disulfide. These 
reactions involve the exchange of a disulfide with a thiol and the formation of a new 
disulfide and a thiol, as seen in equation 1 and 2. From a chemical perspective, thiol-
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disulfide exchange is remarkable. It involves the cleavage and formation of a strong 
covalent bond, being reversible at room temperature in water at neutral pH. This reaction 
has multiple equilibria and leads to the formation of all possible thiols, symmetrical 
disulfides, as well as mixed disulfides as products.  
 
𝑅𝑆𝐻 + 𝑅′𝑆𝑆𝑅′ ⇌ 𝑅𝑆𝑆𝑅′ + 𝑅′𝑆𝐻 
 
(1) 
𝑅𝑆𝐻 + 𝑅𝑆𝑆𝑅′ ⇌ 𝑅𝑆𝑆𝑅 + 𝑅′𝑆𝐻 (2) 
 
Thiolate (RS-) is the active nucleophile in the thiol-exchange and thus the reaction rate 
depends strongly on the solution pH. The thiol in GSH has a pKa of 9.65 and therefore 
only a very small percentage is in the form of thiolate at neutral pH75. The thiol-disulfide 
exchange is effectively switched-off even under slightly acidic conditions86. Likewise, the 
rate of thiol-disulfide exchange depends on the presence of charged substituents in the 
participating thiols and disulfides. For example, the rate of reaction of GSH with positively 
charged peptide disulfides has been seen increase by to 2 orders of magnitude 
compared to the rate of the same reaction with negative counterparts87. 
 
 
Fig. 4 – Thiol-disulfide exchange reaction between an oxidoreductase (thiolate form) and a disulfide.  
 
There are other pathways for the exchange of thiol-disulfides. In cells, these exchanges 
can be performed by catalyzation by a class of enzymes named oxidoreductases. The 
typical enzyme of this group is protein disulfide isomerase. This protein can catalyze 
thiol-disulfide exchange reaction in a wide range of proteins, peptides, and low molecular 
thiols and disulfides88. The activity of this enzyme depends on a pair of cysteines present 
on its motif. Depending on the redox environment and the nature of the substrate, the 
isomerase can catalyze the formation, reduction, or isomerization of disulfide bonds. If 
the active site is oxidized, the enzyme oxidizes protein thiols, otherwise the thiolate of 
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the enzyme attacks disulfide bonds. The overall result of this reaction is the oxidation of 
the enzyme and the reduction of the initial disulfide (figure 4).    
 
1.3 Disulfide bond formation in peptides 
 
Disulfides in proteins play an important role in the maintenance of biological activity and 
conformational stability. Because of its importance, many studies have focused on the 
roles of disulfides as constraints to increase biological activity and as transient 
intermediates in protein folding. For these studies, it is crucial that the disulfide bond 
chemical synthesis is readily accessible. The chemical synthesis of these peptides, e.g. 
Cys(Lys)5Cys – bioreducible poly-L-lysine building block used in this project, containing 
one or more disulfide bonds, require as final step, the formation of disulfide bonds of 
cysteine residues. The general procedure to disulfide formation is by using a mild oxidant 
to form the desired product.  
Among the conventional methods for the formation of disulfide bonds, the air oxidation 
in aqueous medium is one of the most common. Air oxidation usually requires a long-
term synthesis, at basic or neutral pH, and a very diluted concentration of peptide or 
protein to be effective. Nevertheless, it has the advantage of producing a harmless 
reaction byproduct, H2O. A variation to the air oxidation method is the thiol-disulfide 
interchange reaction, with a mixture of oxidized and reduced glutathione. Because the 
air oxidation and the mixed interchange reaction are slow processes, they produce 
thermodynamically controlled products, useful for protein synthesis. In contrast, stronger 
oxidizing agents like I2 and K3Fe(CN)6, that produce kinetically controlled products, are 
often used for simple peptides containing only one or two disulfide bonds. These strong 
agents are such powerful oxidants that the oxidations are usually performed cautiously 
to prevent overoxidation. They have the advantage of being applicable in the acidic 
range, but the byproducts produced by this oxidation require purification. Since the pH 
should be around the basic region, for air oxidation or mixed disulfides, the basic and 
hydrophobic peptides tend to aggregate and precipitate from solution at or near the 
isoelectric points. 
It would be highly desirable to devise a new method for the disulfide formation that is 
similar in mildness to air oxidation, but can be conducted under acidic or neutral 
conditions with no harmful byproducts at an efficient rate. An oxidation process that 
appears to satisfy all these requirements is the use of dimethyl sulfoxide (DMSO)89-91. 
This chemical in known to be a mild oxidizing agent for simple organic thiols, producing 
FCUP 12 
Bulk and microfluidic-assisted preparation of bioreducible polyplexes for gene therapy 
 
H2O and dimethyl sulfide as harmless byproducts. It is miscible with water at all 
concentrations89, and thus a high concentration of DMSO could be envisioned to affect 
the desirable rate of reactions. Furthermore, oxidation by DMSO could also be designed 
to be performed at acidic to neutral pH range, to overcome the limitation of the 
conventional methods of oxidation. This kind of synthesis has been reported to 
synthesize bioreducible polymers by disulfide bond between cysteine-containing 
peptides21, 92.  
 
1.3.1 Mechanism of disulfide formation  
 
The general mechanism of disulfide formation by DMSO has been determined by 
Wallach and Mahon, and a simplified overall reaction can be represented by the following 
equation 3. 
 
 
(3) 
 
The stoichiometry for the reaction requires 2 mol of a thiol and 1 mol of DMSO, and the 
reaction shows a second order kinetics89. Besides, the reaction is strongly catalyzed by 
primary and secondary amines and weakly catalyzed by acids. The rate-determining step 
is the formation of the unstable adduct that is rapidly captured by another free thiol to 
give the disulfide. For this kind of reaction, a pH dependence may be found for cysteines, 
with free α-amino group, while protected amino groups do not show that kind of 
dependence. The pH-dependent kinetics could be rationalized by the rate acceleration 
of disulfide formation at neutral pH by DMSO, when the cysteine is at the amino terminus  
with an unprotected α-amino group. It is plausible that the observed acceleration rate for 
peptides containing a free amino terminal cysteine is due to assistance of the free amino 
group as a general base, and its ability in the steering of the DMSO to the thiol of the 
cysteine. Such regiospecificity is due to the weak interaction between the partially 
negatively charged sulfoxide and the partially positively charged unprotonated α-amine, 
that facilitates the formation of the unstable adduct (figure 5). This kind of assistance will 
not be possible when the free amino group is protected, protonated (at acidic pH) or one 
or more amino acids residues away. 
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Fig. 5 - Representation of the regiosteering of the DMSO to the thiol of the amino terminal cysteine, this is the rate determining step89. 
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1.4 Microfluidics  
 
1.4.1 Outline 
 
The microfluidic technique may be defined as the science and technology of systems 
that process or manipulate small volumes of fluids (typically 10-9 to 10-12 L) using 
channels with dimensions of tens of hundreds of micrometers. The first application of 
microfluidics has been in chemical analysis, for which they offer several useful abilities 
such as small quantities of sample, and high resolution and sensitivity of separations and 
detections. Also, this technology is cost-effective, has short times for analysis, and small 
footprints for the analytical devices93. Microfluidics exploits both its most obvious 
characteristic – small size – and less obvious characteristic of fluids in microchannels, 
such as laminar flow.  
Some of the initial work on microfluidics used silicon and glass, but these materials have 
been displaced by plastics. Silicon is expensive and opaque to visible light, hence it 
cannot be used in optical methods of detection. It is easier to fabricate the components 
required for these systems in elastomers than in rigid materials. Neither glass nor silicon 
has all the properties required for work with biological systems.  
Thus, microfluidic devices have not developed as clones of silicon microelectronic 
devices. Instead, much of the exploratory work on microfluidic chips have been carried 
out in an optically transparent, soft elastomer polymer – poly(dimethylsiloxane), or PDMS 
– which properties are different from the silicon94-95. The ease with which new concepts 
can be tested in PDMS, and its ability to support certain useful components, such as 
pneumatic valves, has made it the key material for research. Silicon and other 
microelectronic materials, like steel or glass, are indispensable to the development of 
microfluidics with the purpose of building specialized systems that require chemical or 
thermal stability. For example, PDMS chips cannot be used in organic synthesis involving 
organic solvents since the microchannels can be partially or totally destroyed.  
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1.4.2 Microfluidic Environment 
 
A microfluidic chip must have a series of components that allow it to fulfill its purposes, 
namely as a method to: (i) introduce reagents and samples, probably as fluids; (ii) move, 
combine and mix those fluids around the chip, and (iii) detect or purify chemical 
components. Two contributions have been the development of soft lithography in PDMS 
as a method to fabricate new devices96, and the development of pneumatically activated 
valves, mixers and pumps based on soft-lithographic procedures97. This lithography 
procedure is much shorter in time than the silicone-based procedure, with typically 2 
days from design to working device for the former compared with one month or more for 
the latter98. 
The use of microfluidics has enabled the comprehension of certain fundamental 
differences between the properties of fluids moving through large channels and fluids 
moving through micrometer channels99. On large scales, fluids mix convectively, similarly 
with the mixing of milk when is swirled into coffee, or with smoke leaving the chimney. In 
microsystems, the opposite is true as fluids do not mix convectively, because when two 
fluid streams come together they flow in parallel, without turbulence. The only mixing that 
occurs is the result of the diffusion of molecules at the interface of the two fluids. When 
mixing is required, components can be made inside the channels that foment that. 
The two most used methods to flow fluids around the microfluidic chip are hydrodynamic 
and electro-osmotic flows. The hydrodynamic flow works by pumping the fluid into the 
microchannels. When an ion-containing fluid is placed in a microchannel that has fixed 
charges on its surface and an electrical potential is applied along the channel, the fluid 
moves as a plug, rather than a parabolic profile characteristic of hydrodynamic flow. The 
advantage of using electro-osmotic flow is that it minimizes the broadening of plugs of 
samples that occur in many pressure-driven systems, and allows very high-resolution 
separations of ionic species.     
 
1.4.3 Mixing Principles 
 
Commonly, the laws that describe the flow at the macroscale also apply to the 
microscale. Nevertheless, the miniaturization process confers additional features that 
can be explored to perform processes otherwise not possible. Microfluidic devices are 
not the miniature of their macroscale counterpart, because many physical properties do 
not scale linearly from large to small devices, such as surface area-to-volume ratio, 
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surface tension and diffusion. The omnipresence of laminar flow is also an important 
feature because viscous forces dominate in the microchannel. It must be noted that 
rather than designing a microfluidic mixer as just a scale-down copy of a macroscale 
mixing device, one should design it in ways that leverage the physical characteristics of 
the mixing in a confined space.  
 
Reynolds Number and Diffusion 
 
Fluid flow is generally categorized into two flow regimes: laminar and turbulent. Laminar 
flow is characterized by smooth and constant flow, whereas turbulent flow is 
characterized by vortices and flow fluctuations. Physically, the two regimes differ in terms 
of the relative importance of viscous and inertial forces. The relative importance of these 
two types of forces for a given flow condition is given by the Reynolds number (Re):  
𝑅𝑒 =
𝜌𝑢𝐷ℎ
𝜇
 (4) 
 where ρ and µ are the fluid density and viscosity, respectively; u is the velocity of fluid 
and Dh is the hydraulic diameter. The hydraulic diameter of the channel is a characteristic 
number that depends on the cross-sectional geometry of the channel, and is given by: 
𝐷ℎ =
4𝐴
𝑃𝑤𝑒𝑡
 (5) 
where A and Pwet are the cross-sectional area and the wetted perimeter of the channel, 
respectively.  
At low Re, the viscous effects dominate inertial effects and a completely laminar flow 
occurs. In the laminar flow system, the fluid streams flow parallel to each other and the 
velocity at any location within the fluid stream is invariant with time when boundary 
conditions are constant. This implies that mass transfer only occurs in the direction of 
the flow, and mixing can be achieved by molecular diffusion100. By contrast, at high Re 
the opposite is observed. The flow is dominated by inertia and characterized by turbulent 
flow. In a turbulent flow, the fluid exhibits motion that is random in both space and time, 
and there is mass transfer in all directions101, (figure 6.a). The transition Re is generally 
expected to be in the range of 1.500 and 2.500 for most situations. For microfluidic 
systems, Re is typically smaller than 100 and the flow is considered essentially laminar 
(figure 6.b). 
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In an environment where the flow is strictly laminar, mixing is largely dominated by 
passive molecular diffusion. Diffusion may be defined as the process of spreading 
molecules from a zone of higher concentration to one of lower concentration by Brownian 
motion, which results in the gradual mixing of material.  
 
Mixing in the Microfluidic Devices 
 
At a macroscale level, mixing is achieved by turbulent flow, which makes possible the 
segregation of the fluid in small domains, thereby decreasing the mixing path. As 
discussed, Re is small for microfluidic systems, implying that hydrodynamic instability 
does not develop; so the flow cannot be turbulent. Owing to this limitation, mixing in 
microfluidic devices is generally achieved by taking advantage of the relevant small 
length, which dramatically increases the effect of diffusion.  
Micromixers are generally design with channel geometries that decrease the mixing path 
and increase contact surface area. Micromixers are generally classified as being active 
or passive. Active micromixers use external energy input to introduce perturbations that 
stir and perturb the fluid for accelerating the mixing process. The type of external input 
employed can be further categorized as pressure field-driven102, ultrasound-driven103, 
temperature-driven104 or magneto-hydrodynamic105. Generally, active micromixers have 
higher mixer efficiency106. However, the implementation of these kind of peripheral 
devices for the external power source into the microdevice, and the complex and 
expensive fabrication process, limit the usage of such devices in practical applications. 
In addition, conditions such as high ultrasound waves or high temperature gradients may 
damage the biological samples. Therefore, active mixers are not a popular choice to 
study biological systems107.  
(b) Laminar flow 
(a) Turbulent flow 
Fig. 6 - Images of different flow patterns. (a) Laminar flow with low Re; (b) Turbulent flow with high Re. 
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Passive mixing devices rely entirely on fluid pumping energy and use special channel 
design and structure in a way that minimizes flow length and maximizes contact surface 
area. These are more convenient to fabricate, less expensive and can be easily 
integrated into more complex devices. This is achieved by splitting the fluid stream using 
serial or parallel lamination108, by hydrodynamically focusing mixing streams109, or by 
introducing ribs or grooves designed on the channel walls, called chaotic advection 
method110. 
 
Passive Micromixers 
 
These devices are designed with a specific geometry that increases surface area and 
decreases the diffusion path. The modified flow pattern is characterized by a shorter 
diffusion path that improves the mixing velocity. As seen before, there are many 
categories of passive mixers, but, in this work, the main emphasis will be on the focusing-
enhanced micromixers.  
 
Flow Focusing 
 
The basic design for hydrodynamic focusing is a long microchannel with three inlets - 
the point of entry of reagents - and one outlet - the point of exit of any possible products 
(figure 7). In hydrodynamic focusing, a central sample solution (supplied from the middle 
inlet) flows within the sheath of outer fluids (supplied from the side inlets), which constrain 
laterally the inner sample flow to achieve a smaller stream and thinner lamination width. 
The extent of the width decrease depends of the volumetric flow rate ratio between the 
sample flow and sheath flows. The greater the flow rate difference, the greater the 
degree of width reduction. The advantage of hydrodynamically focusing the central 
stream is that by doing so, the mixing – by diffusion – will be faster. Notably, the position 
of the focused stream is a function of the relative flow rate ratio of the three inlets, so it 
is possible to direct the stream to a specific outlet, in those cases where there is more 
than one, by changing the relative flow rate of the two side streams111.  
The relative flow rates of the three inlets are generally controlled by pressure sources or 
pumps, already mentioned. The analysis and predictions of the focused stream width is 
based on a simple model on mass conservation principles. The 2D focused stream width 
is computed under these simplified assumptions: 
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i. Flow in the microchannel is steady and laminar; 
ii. Fluids are Newtonian; 
iii. Fluids have the same density in the four channels; 
iv. Fluids flow in a rectangular microchannel; 
v. The four channels have the same height. 
According to the mass conservation principle, the volume of liquid sample that passes 
through the inlet channel (Q2) must match the volume of the focused stream: 
 
𝑄2 = 𝑣2𝑤2ℎ = 𝑣𝑓𝑤𝑓ℎ = 𝑄𝑓 (6) 
 
Leading to: 
𝑤𝑓 =
𝑄2
𝑣𝑓ℎ
 (7) 
where w2 and wf represent the width of the central stream and focused stream, 
respectively. Q2 and Qf are the volumetric flow rates of the central inlet channel and the 
focused stream. h is the height of the channel, and v2 and vf are the average velocity of 
the flow in the central inlet channel and of the focused stream. It can also be concluded 
that the amount of fluid passing the outlet channel must be equal to the total amount of 
fluid supplied from the three inlets: 
𝑄𝑐 = 𝑤𝑐𝑣𝑐ℎ = 𝑄1 + 𝑄2 + 𝑄3 (8) 
 
𝑤𝑐 =
𝑄1 + 𝑄2 + 𝑄3
𝑣𝑐ℎ
 (9) 
where Q1 and Q3 are the volumetric flow rates for the two lateral channels, and vo and 
wo are the average velocities of the flow and width of the mixing channel, respectively. 
When combining (4) and (7), assuming vc and vf have the same values, it is possible to 
obtain the relationship between the width of the focused stream and volumetric flow rate 
of the inlets:  
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This equation provides a simple guideline for predicting the focused stream width. 
However, it does not reflect the effect of other factors such as device structure, channel 
surface, and fluidic property, which could affect the focusing process.  
 
The ratio of volumetric flow rates, equation 11, and the total flow rate, equation 12, can 
also be used to describe the flow system, and be used to characterize and predict the 
width of the focused stream. 
Typically, focusing-enhanced micromixers focus the sample flow only in the horizontal 
dimension. Different authors have proposed microfabricated devices capable of focusing 
the sample vertically and horizontally112-113. Such devices are referred as 3D 
hydrodynamic focusing devices because they add a new dimension to the traditional 2D. 
The problem with these devices is that they have to be prepared by multistep 
photolithography, leading to an increase in fabrication cost.  
It is also important to refer that the velocity profile inside a microfluidic channel in laminar 
flow is typically of the Poiseuille type, i.e. a parabolic shape where the velocity is 
maximum in the center of the channels, and zero at the walls, due to the no-slip boundary 
condition (figure 8.a). This slower velocity near the walls leads to a higher dispersion or 
enlargement of the focused stream near the surface, resulting in a concave shape114 
(figure 8.b). Hence there is a wider distribution of mixing times, which can limit slightly 
time resolution.  
𝑤𝑓
𝑤𝑐
=
𝑄2
𝑄1 + 𝑄2 + 𝑄3
 (10) 
𝑄𝑟𝑎𝑡𝑖𝑜 =
𝑄1 + 𝑄3
𝑄2
 
 
(11) 
𝑄𝑇𝑜𝑡𝑎𝑙 = 𝑄1 + 𝑄2 + 𝑄3 (12) 
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 Fig. 7 - (a) Focusing enhanced mixer. (b) Effect of the ratio of the side pressure to the central pressure on the width of the focused 
stream: (a) 0.5, (b) 1.0, (c) 1.1, and (d) 1.2. Adapted from 115. 
Fig. 8 – (a) The velocity profile inside the channel is of the Poiseuille flow type, where the velocity is maximum in the center of the 
channel and zero at the walls (no slip condition). This slower velocity near the walls typically leads to dispersion and/or enlargement 
of the focused stream, resulting in a concave profile (b).   
Q1 
Q3 
Q2 Qf 
 Wc 
v 
(b) 
FLOW 
Central stream 
Side stream 
Near steady 
state flow 
Uniform flow 
(a) 
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1.5 Scope and aim of this work 
 
Gene delivery efficiency depends significantly on the delivery system chosen. This 
system has to be able to withstand or surpass many biological barriers, and safely deliver 
the genetic cargo inside the cells. Many delivery systems can be adopted for this 
purpose. The system described in this work is based on polymeric colloidal carriers for 
DNA.  
In this project, our aim is to produce and characterize bioreducible polyplexes. The 
bioreducibility property makes the polyplex sensitive to the redox environment of cytosol, 
resulting in degradation of the polymer. This property tackles one of the major barriers 
of nonviral gene delivery, which is the unloading of the gene content. Also, traditional 
bulk self-assembly methods do not allow a fine control of size and polydispersity in the 
production of these nanoparticle. Thus, we propose the application of the microfluidic 
technique that allows a better control over the process of mixing the different components 
and hence on the properties of the polyplexes.  
To achieve our general goals, the following steps will be undertaken: (1) synthesis of the 
bioreducible polymer and plasmid DNA; (2) bulk preparation and characterization of 
bioreducible polyplexes; (2) study of the effect of physiological buffer and ionic strength 
on their colloidal stability; (3) comparison of the physicochemical properties of 
bioreducible polyplexes with non bioreducible polyplexes; (4) study of the effect of 
microfluidics on the structure of polyplexes.  
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2. Materials and Methods 
 
2.1 Materials and reagents 
 
Polyplex preparation 
Poly-L-lysine 0.1% (w/v) H2O wt. 125 000-300 000, and calf thymus DNA (Type I, fibers) 
were purchased at Sigma. HEPES powder (99%) was acquired at Acros Organics. NaCl 
(98%) was acquired at Sigma. Plasmid DNA was obtained by bacteria propagation 
(Appendix I). Glutathione (pharmaceutical second standard) was purchased at Sigma. 
The DNA solution concentration was measured by NanoDrop™ 2000c 
spectrophotometer. The microscope used for the microfluidic experiments was a Nikon 
Eclipse Ti, with a Plain Fluor 20x/0.45 objective, and a Lambda LS 145W Xenon bulb as 
fluorescence excitation source. The camera was a Andor™ Neo. 
 
Bioreducible poly-L-lysine 
Bioreducible poly-L-lysine monomer (88.9%) was purchased at POP-UP, a service unit 
of peptide synthesis provided by the Faculty of Sciences of the University of Porto. 
DMSO (99.5%) and PBS tablets were purchased at Sigma. The Amicon 10 000 MW 
centrifuging filters were acquired at Merck. 
 
2.2 Charge ratio calculation  
 
Throughout the work, the polymer/DNA charge ratio, CR, is defined according to 
 
where C+ is the molar concentration of positive charge present in the protonated amine 
groups of lysine and C- is molar concentration of negative charge due to the phosphate 
groups of DNA.  
The negative charge of the phosphate groups of DNA present in solution were 
determined by  
𝐶𝑅 =  
𝐶+
𝐶−
 (13) 
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where MWbp = 618 g.mol-1 and CDNA is the concentration of DNA in the solution in g.L-1. 
The MWbp does not take into consideration the sodium counter ions because their mass 
contribution is not measured when using nanodrop to determine DNA concentration of 
the solution. The factor of 2 is due to the two negative charges per base pair (bp) of DNA. 
The positive charge of the amino groups of PLL present in solution were determined by 
 
where MWPLL = 129.18 g.mol-1 and CPLL is the concentration of PLL in the solution in g.L-
1. The MWPLL does not take into consideration the bromide counter-ions because the PLL 
solution, bought from Sigma, only considers PLL mass contribution. There is only one 
charge for which lysine, so the molar concentration of positive charges is equal to the 
molar concentration of poly-L-lysine. 
The positive charge of the amino groups of bPLL present in solution were determined by  
 
where MWbPLL = 906.47 g.mol-1 and CbPLL is the mass concentration of the solution. The 
MWbPLL was obtained by mass spectroscopy. The factor of 5 is due to the five positive 
charges of each building block. 
All stock solutions of DNA, PLL and bPLL, used to prepare all samples, had a 
concentration of 1.00 g.L-1. 
 
  
𝐶− =  
𝐶𝐷𝑁𝐴
𝑀𝑊𝑏𝑝
∗ 2 (14) 
𝐶+ =  
𝐶𝑃𝐿𝐿
𝑀𝑊𝑃𝐿𝐿
 (15) 
𝐶+ =  
𝐶𝑏𝑃𝐿𝐿
𝑀𝑊𝑏𝑃𝐿𝐿
∗ 5 (16) 
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2.3 Bulk preparation 
 
All polyplex systems were prepared similarly, following the procedures stated below. 
These systems are poly-L-lysine with calf thymus DNA (PLL-cfDNA), poly-L-lysine with 
plasmid DNA (PLL-pDNA), bioreducible poly-L-lysine with plasmid DNA (bPLL-pDNA), 
and monomeric bioreducible poly-L-lysine CK5C-pDNA. 
 
2.3.1 Poly-L-lysine and DNA system preparation in water  
 
The PLL-DNA complexes were prepared as follows: a fixed volume of PLL (0.500 mL) 
of variable concentration was added to a solution containing DNA (0.500 mL) on a 
magnetic mixer. The final concentration of DNA was 11.5 µg.mL-1 (0.0115 mg per 
sample).  The samples were subsequently vortexed for 10 seconds at 1200 rpm and left 
for 30 min on a mixing board before measurements.  
 
2.3.2 Poly-L-lysine and DNA system preparation in buffer 
 
Buffer preparation 
The following buffer solutions were prepared: 80 mM HEPES with 80, 120, 280, 400 and 
600 mM of monovalent salt. In a falcon tube, a mass of 0.1906 mg of HEPES (99%) was 
dissolved in 10 mL of DI water. The pH was then adjusted to 7.4, normally 100 μL of 1 
M NaOH. To complete the monovalent salt concentration, NaCl was added. To 
determine the quantity of NaCl to add, one needs to consider de sodium ions present 
from the pH adjustment, and the ionization of HEPES.  
The concentration of Na+, in this case, was 10 mM. At pH 7.4, the concentration of 
ionized HEPES was 35.4 mM. To prepare a buffer with 80 mM of monovalent salt, the 
quantity of NaCl to add was only 34.6 mM equivalent to 0.0215 g. 
 
Addition of buffer after formation (Path I) 
A stock solution of 80 mM HEPES and 80 mM monovalent salt at pH 7.4 was used to 
prepare the samples. A fixed volume of PLL solution (0.188 mL) was added to the DNA 
solution (0.188 mL) on a magnetic mixer.  The final concentration of pDNA was 11.5 µg 
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mL-1.  The samples were subsequently vortexed for 10 seconds at 8000 rpm and left for 
30 min on the mixing board. Finally, 0.125 mL of buffer was added to the polyplex 
solution. The solution was vortexed at 8000 rpm for 5 seconds and left to rest for 30 
minutes before measurements. 
The same procedure was applied to the other buffered samples. 
 
Formation in buffer (Path II) 
A stock solution of 80 Mm HEPES and 80 Mm monovalent salt at pH 7.4 was used to 
prepare the PLL and DNA solutions. To a fixed volume of PLL (0.188 mL) of variable 
concentration, 0.062 mL of buffer was added. The same was done for the DNA solution. 
Then, the PLL solution (0.250 mL) was added to the DNA solution (0.250 mL) on a 
magnetic mixer. The final concentration of DNA was 11.5 µg mL-1. The samples were 
subsequently vortexed for 10 seconds at 8000 rpm and left to rest for 30 min before 
measurements.  
Same procedure was applied to the other buffered samples. 
 
2.3.3 Glutathione test  
 
All polyplex systems were prepared similarly, following the procedures stated below. 
These systems are poly-L-lysine with plasmid DNA (PLL-pDNA), bioreducible poly-L-
lysine with plasmid DNA (bPLL-pDNA), and monomeric bioreducible poly-L-lysine CK5C-
pDNA. 
A stock solution of 208.6 mM GSH at pH 7.3 was used to prepare the samples. A fixed 
volume of polymer solution of variable concentration, was added to the pDNA solution 
on a magnetic mixer.  The final concentration of pDNA was 11.5 µg mL-1 (0.00575 mg 
per sample).  The samples were subsequently vortexed for 10 s at 1200 rpm and left for 
30 min on the mixing board. Finally, it was added a determined volume of GSH to the 
polyplex solution, to a variable final concentration ranging from 10-40 mM. In table 1 are 
shown the volumes of reagents to prepare samples stated in this section. The DLS 
measurements were performed immediately afterwards, unless otherwise stated.  
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Table 1 – Volumes of polymer, DNA and GSH added to prepare samples for the study of the effect of glutathione on polyplexes. 
 
Final concentration of GSH /mM Vpolymer /mL VDNA /mL VGSH /mL 
10 0.238 0.238 0.0240 
20 0.226 0.226 0.0479 
40 0.202 0.202 0.0959 
 
 
2.4 Microfluidic preparation 
 
2.4.1 Microfluidic device fabrication 
 
PDMS microfluidic devices were fabricated by using a microfabrication protocol establish 
by the microfluidics group at INL and a Sylgard® 184 PDMS kit. The silicon master is 
prepared at the cleanroom with photolithography techniques. The silicon wafer with the 
requested design (figure 9.a) is then put into a Petri dish and covered with 
PDMS:crosslinker (10:1). The master is placed under vacuum for 40-60 min. This 
removes trapped air in the PDMS. The next step is the curing process which involves 
the hardening of the PDMS. For this, the master is maintained in an oven for 3 h at 65 
ºC. After curing, the PDMS is cut around the channels, and then peeled from the master. 
A puncher is used to create the inlets and outlet. The PDMS stripes and a coverslip are 
washed with water and ethanol. The PDMS surface with the channels and the coverslip 
are then exposed to an oxygen plasma treatment. Finally, the exposed surfaces are 
gently pressed together. A solution of 1%(w/w) of F127 is slowly flown through the 
microchannels. This compound adheres to the channels walls making them hydrophilic.  
 
2.4.2 Poly-L-lysine and plasmid DNA in water 
 
For the flow visualization, the MF device was mounted on an inverted microscope stage 
(Nikon Eclipse Ti) with a s Point Fluor 20x/0.45 objective. Two programable syringe 
pumps were used to control the fluid flow rates independently. The setup is shown in 
figure 9.b. The device consists of three inlets and one outlet. The side inlets were 
connected to PLL and the mid inlet was connected to pDNA with fluorescein (11.7 μM). 
After the DNA stream has entered and the hydrodynamic focusing established, the 
products in the outlet stream are collected after 3-5 minutes to allow steady state, tracked 
by fluorescence microscopy. The magnitude of shear stresses applied to DNA was 
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controlled by altering the ratio of the flow rate (QR) in the side streams to the middle 
stream, see table 2.  
 
 
Applying equation 17, one can determine the initial concentrations of PLL and pDNA to 
use for each flow rate ratio for charge ratio 7. The concentrations can be found in table 
3. 
 
 
Table 2 – Selected flow ratios to prepare the polyplexes. Flow rates Qi and Qs were determined by applying equations 11 and 12 
(Q2=Qi, DNA inlet, and Q1=Q3=Qs, PLL inlet).  
[𝑃𝐿𝐿]𝑠𝑒𝑟𝑖𝑛𝑔𝑒 =
𝑄𝑖
2𝑄𝑠
𝐶𝑅[𝑝𝐷𝑁𝐴]𝑠𝑒𝑟𝑖𝑛𝑔𝑒 (17) 
Qtotal Qratio Qi /μL.min-1 Qs /μL.min-1 
11 
2 3.667 3.667 
10 1.000 5.000 
30 0.355 5.323 
50 0.216 5.392 
55 
2 18.333 18.333 
10 5.000 25.000 
30 1.774 26.613 
50 1.078 26.961 
(a) (b) 
Fig. 9 – (a) Representation of the design of the channels on the microchip; (b) microfluidic setup used to prepare PLL/pDNA 
polyplexes.   
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Table 3 – Determined concentrations of pDNA, fluorescein and PLL, for charge ratio 7, for microfluidic-assisted preparation of 
polyplexes.  
 
 
2.5 Synthesis of bioreducible polymer  
 
Procedure 
The bioreducible poly-L-lysine was synthesized by oxidative polycondensation as 
described by many authors21, 89, 92, 116. Briefly, 61.7 mg of CKKKKKC was dissolved in 
1.420 mL phosphate buffered saline (PBS) and 0.426 mL DMSO. The reaction was 
carried out at room temperature for 5 days. The bPLL was then purified by centrifuging 
using a centrifugal filter with a 10 000 MW cut-off. The purified bPLL was resuspended 
and lyophilized. A total of 9.1 mg of bPLL were synthesized. A scheme of the synthesis 
is shown in figure 10. 
Qratio [pDNA]syringe /μg.mL-1 [Fluorescein] /μM [PLL]syringe /μg.mL-1 
2 23.0 
11.7 
33.4 
10 115 33.4 
30 345 33.4 
50 575 33.4 
Fig. 10 - Scheme of the polycondensation of CK5C and purification process. 
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2.6 Characterization techniques  
 
2.6.1 Dynamic light scattering 
 
The two main characteristics of colloids that are used by DLS are the Tyndall effect 
(scattering) and Brownian motion. Among other factors, the intensity of scattered light 
depends on the scattering angle (θ) and the observation time (t). This leads to the 
development of DLS in which the time dependence of the intensity is measured117.  
This time dependence of scattering intensity arises from the fact that colloidal particles 
are not static in suspension, rather they move in a random fashion by the Brownian 
motion effect. When a monochromatic radiation goes through a collection of particles, it 
scatters due to physical interaction. Since particles are moving in space, the distance 
travelled by the scattered light from the particle to the detector differs with time117-118.  
In DLS, the characteristic time of fluctuations in the scattered intensity is measured, and 
it depends on the diffusion coefficient of the particles undergoing Brownian motion. 
Larger particles have inherently slower Brownian motions, diffusing slower than smaller 
particles119. In terms of scattered light, large agglomerates with slow Brownian motion 
will have slower intensity fluctuations than the smaller particles with high Brownian 
motion, thus allowing the system to correlate slow intensity fluctuations with large size 
particle (figure 11). Quantitative information regarding the time scale of these fluctuations 
is obtained by a signal processing technique known as autocorrelation120. The essence 
of this technique lies in analyzing the correlation function to determine the particle size 
information. For a particle suspension undergoing Brownian motion, the autocorrelation 
function decays exponentially with the delay of time τ, and is given as,  
Fig. 11 – Schematic illustration of a Dynamic Light Scattering measurement, highlighting the differences between small and large 
particle signals. Adapted from 119. 
𝑔1(𝜏) = 𝐴×𝑒−𝐷𝑞
2𝜏 + 𝐵 (18) 
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where A is the amplitude of the correlation function, B is the baseline, D is the 
translational diffusion coefficient of the particles, and q is the magnitude of the scattering 
vector. The hydrodynamic diameter, dH, is obtained from the translational diffusion 
coefficient, D, using the Stokes-Einstein relationship: 
 
where dH is the hydrodynamic diameter, kB is Boltzmann’s constant, T is the absolute 
temperature, μ is the viscosity and D, already mentioned above118. The diffusion 
coefficient is acquired by fitting the correlation function with a suitable algorithm, resulting 
in mean size, z-average, and polydispersity index values.  
In many practical systems, there exists a distribution of particle sizes and scattering from 
such polydisperse population of particles leads to deviation from the expected single 
exponential decay of the correlation function. For a polydisperse distribution of diffusion 
coefficient, equation 18 can be written as a sum of exponentials, weighted by their 
amplitudes. For a continuous distribution, each D contributes its own exponential, and 
the observed correlation function can be represented as an integral weighted by the 
distribution function, which can be expressed as  
where Γ = Dq2 is the decay constant for a given size. The distribution G(Γ) represents 
the relative intensity of light being scattered with decay constant Γ and will depend on 
the volume fraction and size of scatterers. The occurrence of measurement noise, 
baseline drifts, dust interference and the exponential function under the integral all put 
together make this equation ill-conditioned.   
There are different ways to extract the diffusion coefficient (particle size) information from 
the measured data in polydisperse samples. One approach is to calculate the mean and 
variance of the distribution. Under this approach, the method of cumulants 121 has been 
widely used to analyze narrow polydispersity in DLS experiments and is the only method 
that is currently recommended122. 
𝑑𝐻 =
𝑘𝐵𝑇
3𝜋𝜇𝐷
 (19) 
𝑔1(𝜏) = ∫ 𝐺(Γ) exp(−Γ𝜏) 𝑑Γ
∞
0
 (20) 
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In this method used in DLS analysis, the term exp(-𝛤𝜏) in equation 20 can be expanded 
about a mean value ?̅? such that, 
The relative magnitude of contributions of the term in the bracket falls of rapidly with 
increasing order. When G(Γ) is relatively narrow, terms with order 3 and above can be 
neglected 117, 120, substituting equation 21 in equation 20, 
 
By definition, the mean (?̅?) and variance (𝜇2) of the distribution G(Γ) are  
 
Thus, equation 22 becomes, 
 
When 𝜇2𝜏
2 ≪ 1, equation 25 can be simplified, 
 
𝑒𝑥𝑝(−Γ𝜏) = 𝑒𝑥𝑝(−𝛤𝜏)× exp(−[Γ − Γ̅]𝜏) 
= exp(−𝛤𝜏) ×[1 − (Γ − Γ̅)𝜏 + (Γ − Γ̅)2
𝜏2
2!
+ ⋯ ] 
(21) 
𝑔1(𝜏) = 𝑒(−?̅?𝜏)[∫ 𝐺(Γ)𝑑Γ
∞
0
− 𝜏 ∫ 𝐺(Γ)Γ𝑑Γ + 𝛤𝜏 ∫ 𝐺(Γ)𝑑Γ
∞
0
+
𝜏2
2
∞
0
∫ (Γ − Γ̅)2𝐺(Γ)𝑑Γ
∞
0
] 
(22) 
𝛤 = ∫ 𝐺(Γ)Γ𝑑Γ
∞
0
 (23) 
𝜇2 = ∫ 𝐺(Γ)(Γ − Γ̅)
2𝑑Γ
∞
0
 (24) 
𝑔1(𝜏) = 𝑒−Γ̅𝜏[1 +
𝜇2𝜏
2
2
] (25) 
𝑔1(𝜏) = 𝑒−Γ̅𝜏+
𝜇2𝜏
2
2  (26) 
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Taking the natural logarithm, adding the background B in equation 26 gives 
 
This equation is the one that is traditionally used in cumulants analysis. By fitting 
ln[𝑔1(𝜏)] to quadratic in 𝜏, one can obtain the mean, Γ̅ and the variance, 𝜇2.  The ratio of 
variance to the square of the mean is a measure of the polydispersity of the diffusion 
coefficient and this is very often represented as a polydispersity index, equation 28. 
Finally, the mean Γ̅ is then used to determine the diffusion coefficient,  
where q is a constant associated with the angle of the detector. 
 
  
ln[𝑔1(𝜏)] = 𝑙𝑛𝐵 − Γ̅𝜏 +
𝜇2𝜏
2
2
  (27) 
𝑃𝐼 =
𝜇2
Γ̅2
 (28) 
𝛤 = 𝐷𝑞2 (29) 
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2.6.2 Electrophoretic mobility 
 
Zeta potential is a physical parameter which is related to the surface charge of any 
particle in suspension. It helps predict the long-term colloidal stability. When a charged 
particle is dispersed, and adsorbed double layer develops on its surface. The inner layer 
consists of ions/molecules of the opposite charge to that of the particle – Stern layer. 
The outer layer, the electrostatic effects due to the surface charge on the particle 
decreases, making it dynamic – diffuse layer.  
Due to the electrostatic field of the charged nanoparticles, a diffuse layer consisting of 
both same and opposite charged ions/molecules grow beyond the Stern layer. The Stern 
layer along with the diffuse layer forms the electrical double layer – EDL123  (figure 12). 
The composition of the diffuse layer may vary depending on pH, ionic strength, 
concentration etc. When an electric field is applied to such dispersion, the charged 
particles move towards the opposite electrode. Within the diffuse layer there is a 
hypothetical plane which acts as the interface between the moving particle and the 
dispersant around it while the electric field is applied. This plane is the characteristic 
slipping/shear plane and ZP is the potential at this particle-fluid interface118.  
 
Fig. 12 –Representation showing the electric double layer on a positively charged particle. Immediately on top of the particle surface 
is a strongly adhered layer (Stern layer) comprising of ions of opposite charge i.e. negative ions. Beyond this layer, a diffuse layer is 
created consisting of both negative and positive ions. During electrophoresis, the particle with adsorbed EDL moves towards the 
electrodes i.e. positive electrode in this case, with the slipping plane becoming their interface between the mobile particles and 
dispersant. The ZP is the electrokinetic potential at this slipping plane.  Adapted from 119. 
FCUP 35 
Bulk and microfluidic-assisted preparation of bioreducible polyplexes for gene therapy 
 
Zeta potential cannot be measured directly and is deduced from electrophoretic mobility 
of charged particles under an applied electric field. The electrophoretic mobility - 𝜇𝑒 - of 
the particles is first calculated as in (equation 30) 
 
where V is particle velocity and E is electric field, both known quantities. The ZP is then 
calculated from the obtained 𝜇𝑒 by the Henry’s equation (equation 31) 
 
Where 𝜀𝑟 is the permittivity of vacuum, 𝜀0 is the dielectric constant, 𝜉 is the ZP, f(Ka) is 
henry’s function and 𝜂 is the viscosity. When the thickness of EDL is much bigger than 
the particle itself due to smaller particles dispersed (≤100 nm)118, the value f(Ka) is taken 
as 1 and the Henry’s equation simplifies to the Hückel equation (equation 32)  
 
 
 
The used method to determine the ZP of the particles described in this work was the 
electrophoretic light scattering. This is based on the fact that mobile particles scatter light 
in a different frequency than the original light source, and this frequency is proportional 
to the speed of particles. In instrument, the laser is split into two and one is used as 
reference while the other goes through the sample. The scattered light from the sample 
is combined with the reference beam to determine the shift. The magnitude of particle 
velocity is deduced from that shift. Then, ZP is measured through the equations listed 
previously. 
ZP data is popular because it can relate to colloid stability. Guidelines classifying NP-
dispersion with absolute ZP values of 0-10 mV, 10-20 mV, 20-30 mV, and ≥ 30 mV, as 
highly unstable, relatively stable, moderately stable and highly stable, respectively, are 
common118, 124. 
𝜇𝑒 =
𝑉
𝐸
 (30) 
𝜇𝑒 =
2𝜀𝑟𝜀0𝜉𝑓(𝐾𝑎)
3𝜂
 (31) 
𝜇𝑒 =
2𝜀𝑟𝜀0𝜉
3𝜂
 (32) 
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2.6.3 DLS and EM measurements 
 
Bulk measurements procedure  
 
The hydrodynamic radius and the zeta potential of the poly-L-lysine – DNA complexes 
were determined with a SZ-100 apparatus from Horiba (Japan). Samples were prepared 
as described in the general procedure. Dynamic light scattering measurements were 
carried out at 25 °C, at a detection angle of 173° and laser wavelength of 532 nm. Zeta 
potential measurements were carried out in an electrophoresis cell at 25 °C. The average 
values of size (z-average) and zeta potential were calculated with data obtained from 
five runs. 
 
Microfluidic measurements procedure  
 
The hydrodynamic radius and the zeta potential of the poly-L-lysine – DNA complexes 
were assessed by using a SZ-100 (Horiba, Ltd.). Samples were prepared as described 
previously. Dynamic light scattering measurements were carried out at 25°C, detection 
angle of 173° and 90º, and laser wavelength of 532 nm. The average values of size were 
calculated with a data obtained from five runs. 
 
2.6.4 DLS Characterization 
 
Throughout this work, dynamic light scattering (DLS) was the main characterization 
method.  
The autocorrelation function can be directly fit with different models, such as single or 
double-exponential decay and cumulants fit, or go through an inverse Laplace transform 
into an intensity vs. size distribution. Although convenient, the inverse Laplace transform 
is ill-defined and is not suited for polydisperse samples were the different sizes are not 
well-separated. Using the inverse Laplace transform in such cases may result in over-
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interpretation of the data. Throughout this work we chose the cumulants and double-
exponential fits, since they are less model-dependent125-127. 
 
This technique applies a series of physical concepts, reviewed in section 2.6.1, that 
results in a mean particle size (z-average) and polydispersity. For the whole bulk 
preparation of polyplexes, the z-average was determined by the equipment at 25ºC and 
at a scattering angle of 173º. Some of the autocorrelation curves obtained for 
bioreducible polyplexes in water at five different charge ratios are illustrated in figure 13. 
For the microfluidic preparation, another approach was taken. DLS measurements were 
made for two scattering angles, 173º and 90º. Then, using a MATLAB routine was 
implemented that uses a non-linear cumulant analysis120 to obtain a z-average (diameter) 
that is weighted by both 173º and 90º measurements. What this routine does is extracts 
the mean decay constants (Γ̅) of all the measurements, at 173º and 90º, by fitting the 
DLS data with this new non-linear fit equation (equation 33). 
 
An example of the application of this equation to fit the DLS data are show in figure 14.a.  
𝑔(2)(𝜏) = 𝐵 + 𝛽 {exp (−Γ̅𝜏) [1 +
1
2
𝜇2𝜏
2]} (33) 
Fig. 13 – Normalized autocorrelation functions obtained from DLS measurements for bioreducible polyplex samples at five different 
charge ratios and fixed DNA concentration. Autocorrelation curves for () polyplexes at CR = 1.5, () polyplexes at CR = 2, () 
polyplexes at CR = 2.1, (*) polyplexes at CR = 2.5, (+) polyplexes at CR = 5, () polyplexes at CR = 10.  
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Fig. 14 – Application of the non-linear fit to DLS measurements, at 173º and 90º, of samples PLL-pDNA prepared by microfluidics 
(QR = 2 QT = 11 μL.min
-1).  (a) Illustrative measurement at 173º () and 90º (), (b) Application of equation 34 to extrapolate the 
diffusion coefficient weighted by both scattering angle data. This extrapolation was done by having five measurements at 173º () 
and five measurements at 90º (). 
 
After determining the mean decay constants for each measurement, the diffusion 
coefficient can be extrapolated from equation 34. 
Where q = (4π/λ)sin(θ/2), with θ corresponding to the scattering angle in radians. An 
example of this extrapolation can be seen in figure 14.b. This extrapolation was done by 
having five measurements at 173º (high q2) and five measurements at 90º (low q2), for 
each sample. After determining the coefficient, the Stokes-Einstein equation is applied, 
which results in an averaged hydrodynamic diameter. 
 
  
Γ̅ = 𝐷𝑞2 (34) 
(a) (b) 
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3. Results and discussion  
 
3.1 Outline 
 
The basic aims of this project are (i) to provide information about the effect that the 
bioreducibility property has on the physicochemical properties of the complex and (ii) 
study the influence of the mixing process on the final structure of the polyplex. The 
chosen polymer for the production of these particles was poly-L-lysine (PLL), which is a 
biopolymer composed solely by the amino acid lysine (figure 15.a). This polymer at 
physiological pH has most of the amine residues protonated (pKa = 10.536). In the case 
of the bioreducible poly-L-lysine (bPLL) used in this work, most of the features remain, 
with the difference that between every sequence of five lysines, there is a disulfide bond 
resulting from the oxidation of monomeric CK5C. Cysteine-terminal groups allow the 
formation of disulfide bonds, which are cleavable in the reducing environment of the 
intracellular medium81, 128 (figure 15.b). This property also has the advantage of being 
less toxic than regular polymers, due to the fast-intracellular degradation by cleavage of 
the disulfide bonds129.                                                                                                                 
 
Fig. 15 – Polymer backbones used to prepare the polyplexes described in this work. (a) poly-L-lysine – PLL; (b) bioreducible poly-
L-lysine – bPLL.  
The structure and size of polyplexes can be influenced by various parameters, such as: 
(i) the properties of the constituting polymers (e.g. molecular weight and charge density), 
(ii) overall composition (e.g. mixing ratio between DNA and PLL), (iii) preparation 
method, and (iv) the properties of the medium in which polyplexes are present (e.g. pH 
and ionic strength). In order to achieve a greater control over the size and structure of 
these particles, the influence of some of these parameters was investigated. The 
systems that we investigated were: ctDNA-PLL, pDNA-PLL and pDNA-bPLL. 
(b) (a) 
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3.1.1 Mixing order of PLL and DNA 
 
It has been reported that the mixing order of polyelectrolytes not only affects the size of 
the resulting particles, causing up to a 2-fold change in size, but also the stability of these 
complexes to NaCl130. For example, at CR=3, if the DNA is added to the polymer, there 
is always an excess of positive charge in the complexes and repulsive forces between 
them help maintain colloidal stability. However, if the same polyplex mixture is prepared 
by addition of polymer to DNA, the negative charge of the initial coacervates will reach a 
neutral value half way through the addition of polymer. As a result, neutral particles can 
flocculate if polyelectrolytes are mixed in the wrong order34, 131. Hence, in this work we 
wanted to determine whether this was the case in the pDNA-PLL system, i.e. if adding 
pDNA to PLL or PLL to pDNA could result in observable differences. Two sets of 
polyplexes were prepared. In the first set the pDNA was added to the PLL for CR = 1 
and 3 (DNA on PLL). In the second set the opposite was done (PLL on DNA). Table 4 
shows the results. 
 
Table 4 – Study of the effect of the mixing order for the PLL-pDNA system, at fixed concentrations, CR = 1 and 3. 
 DNA on PLL PLL on DNA 
CR Size /nm Std /nm PDI Size /nm Std /nm PDI 
1 93.4 2.9 0.162 85.9 1.5 0.182 
3 65.5 3.0 0.224 69.1 3.0 0.204 
 
DLS is especially useful to provide information on the hydrodynamic diameter and 
polydispersity. Figure 16.a and 16.b show the autocorrelation functions measured with 
DLS for both CR = 1 and CR = 3, respectively. Each sample is measured in triplicate and 
the reproducibility across these replicates is very good. For CR=3, the two samples have 
almost perfectly overlapping autocorrelation curves, indicating very small differences. 
Indeed, the fitting algorithm of the instrument software (based in the cumulants method) 
yielded sizes that are essentially identical (table 4). For CR=1, there is some mismatch 
between the autocorrelation curves for the two different orders of addition. The 
instrument software fit also provided results that were more different than for the CR=3 
case, but taken together, these differences do not seem very significant.  
This leads to the assumption that for these conditions, whether pDNA is added to PLL 
or vice-versa seems to be of small significance. This is in agreement with other studies 
in the literature, where the mixing order did not have an effect on the final structure of 
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the polyplex131-133. Nonetheless, for consistency, unless otherwise noticed, the 
polypeptide was always added to pDNA.  
 
Other study134 addresses the influence of solution inhomogeneity on structure and 
morphology of polyplexes. The inhomogeneity is induced by mixing two solutions 
containing, respectively, protamine and DNA, with different relative concentrations, but 
aiming to produce the same final concentration. This study showed that the relative 
population of compacted and unfolded structures are very highly dependent on the 
method of preparation of the mixtures containing polymer/DNA. In this study, the solution 
inhomogeneity increases with increasing charge ratio. Different populations of 
compacted and unfolded may be obtained.   
 
3.1.2 Effect of physiological buffer, ionic strength and order of mixing 
 
As mentioned previously, pH influences the protonation of the peptide, and therefore its 
charge density. Hence, together with the ionic strength, these two parameters are 
expected to influence the electrostatic attraction between the two oppositely charged 
polymers, and the colloidal stability of the resulting polyplexes. This becomes significant 
if one recalls that these particles have applications in biological systems, and hence, 
complexation and stability in a buffer that resembles physiological media should be 
studied.  
Fig. 16 – DLS autocorrelation functions for PLL-pDNA polyplexes with different charge ratios, at fixed DNA concentration (11.5 
μg.mL-1). The data were collected at 25ºC with scattering angle θ = 173º. (a) Study of mixing order at CR 1, () first measurement 
for PLL, () second measurement for PLL, (*) third measurement for PLL, (+) first measurement for pDNA, () second 
measurement for pDNA, () third measurement for pDNA; (b) study of mixing order at CR 3 () first measurement for PLL, () 
second measurement for PLL, (*) third measurement for PLL, (+) first measurement for pDNA, () second measurement for pDNA, 
() third measurement for pDNA. 
(a) (b) 
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With this in mind, an experimental design was created to understand what kind of 
influence the buffer pH and ionic strength have on the aggregation and structure of the 
polyplexes. Thus, several 20 mM HEPES buffers at pH 7.4 with an ionic strength ranging 
from 20 to 150 mM were prepared and tested on the polyplexes. Two different 
experiments were performed. In the first, the buffer was added to the reagents (PLL and 
pDNA), and then the polyplexes were prepared (figure 17.a). In other words, PLL and 
pDNA are mixed at physiological pH and ionic strength. In a second experiment, the 
polyplexes were prepared first in water and the buffer was added after (figure 17.b). In 
other words, PLL and pDNA are mixed at very low ionic strength.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 – Experimental design for the two buffer addition methods. (a) polyplex preparation in buffer, with the polymer and pDNA 
already in the presence of buffer; (b) Buffer is added after mixing of polymer and pDNA in water.  
 
 
  
(a) 
(b) 
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3.2 Bulk preparation 
 
3.2.1 Poly-L-lysine and DNA 
 
Preparation in water: size differences between ctDNA and pDNA polyplexes 
 
For studies with poly-L-lysine (125k – 300k), two types of DNA were studied, calf thymus 
DNA and plasmid DNA (pGL3, control vector, 5256 base pairs). While the plasmid DNA 
is a small circular DNA double helix, and very monodisperse, calf thymus is long and 
polydisperse. 
In an initial study, our aim was to investigate the dependence of polyplex size with 
concentration. The charge ratio between positive (from PLL) and negative charges (from 
DNA) was fixed at 3. The results can be seen in figure 18. Aside from the relationship 
between size and DNA concentration, this study helped to determine the optimum 
quantity of DNA to use in the following experiments, which was 11.5 μg.mL-1. In this way, 
it was possible to minimize plasmid expenditure and maintain a good DLS signal. 
As it is easy to see, there is an overall decrease in size of the polyplexes prepared with 
the circular monodispersed DNA.  This difference is most likely to be a result of the 
structural differences between both types of DNA. While pDNA is circular and highly 
monodisperse, ctDNA is very polydisperse (Mw/Mn=5.2135) with an average molecular 
weight of 13 kbp, indicating that not only the polymer is longer, but there is also a 
significant fraction with much longer lengths. We hypothesize that while complexation 
between DNA and PLL is occurring, longer DNA chains are most likely to interact with a 
larger amount of PLL, nucleating into longer particles.  
Along with the size differences between ctDNA and pDNA, it is also clearly noticeable 
that in both cases, the size increases with increasing DNA concentration. The maximum 
concentration tested in these experiments is 200 μg.ml-1 DNA and 249 μg.ml-1 PLL 
(CR=3), together resulting in a mass fraction of roughly 0.05%. This means that these 
samples are all highly dilute, which help exclude the possibility of having obstruction 
effects from the particles to each other that would slow down the apparent diffusion 
coefficient and provide overestimated sizes. Hence, the increase in size observed by 
DLS is a real effect. A possible justification for this behavior is that a larger concentration 
of the individual polymers in the beginning of the complexation process facilitate 
nucleation into larger particles.  
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Fig. 18 – Size dependence of polyplexes of poly-L-lysine with calf thymus () and plasmid () in water, as a function of DNA 
concentration, and CR=3. 
 
After fixing the DNA concentration at 11.5 μg.mL-1, PLL / DNA system was study varying 
the charge ratio from 0.5 to 10. The size profile, obtained by DLS, can be observed in 
figure 19.a, and the zeta potential profile can be seen in figure 19.b. 
In terms of size, both preparations have a diameter peak at CR = 1.6, that coincides with 
a low zeta potential. This means that the polyplex is near charge neutrality. When zeta 
potential is around 0 mV, an increase in size may be detected due to the formation of 
particle aggregates. Visually, the CR = 1.6 samples precipitate not long after the 
measurements, further supporting the near charge neutrality idea. At higher charge 
ratios, it is observed a stabilization of the size at around 130 nm for calf thymus and 60 
nm for pDNA. Zeta potential measurements allow to see an inversion of surface electric 
potential from negative at low CR (i.e. excess of DNA) to positive at high CR, which was 
expected. The negative surface potential may indicate that the DNA is partially 
condensed. Other studies have also found similar size and zeta potential shifts using 
PEI136 and polystyrene-based137 polymers, observing a point of particle charge 
neutralization at CR = 3 and 0.6, respectively.  
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Fig. 19 - Study of complexation of poly-L-lysine with DNA, calf thymus () and plasmid (), in water as a function of charge ratio, 
at fixed DNA concentration (11.5 μg.mL-1). (a) size of polyplexes against charge ratio; (b) zeta potential of polyplexes against charge 
ratio. 
 
Table 5 – Size and polydispersity values obtained by DLS for bioreducible poly-L-lysine/pDNA systems, at fixed concentration (11.5 
μg.mL-1).   
 PLL / Calf thymus system PLL-pDNA system 
CR Size /nm Std /nm PDI Size /nm Std /nm PDI 
0.5 118.1 2.9 0.338 91.9 14.5 0.505 
1 116.4 0.4 0.25 86.5 2.2 0.092 
1.5 180.4 1.5 0.209 82.5 1.2 0.145 
1.6 188.6 1.8 0.201 99.4 2.3 0.198 
1.7 167.6 1.6 0.156 91.0 1.3 0.218 
2 148.5 1.8 0.176 66.8 1.0 0.249 
3 132.7 0.8 0.197 69.9 3.6 0.415 
5 127.7 0.8 0.204 64.6 1.2 0.306 
7 135.2 0.5 0.208 62.6 1.1 0.322 
10 132.3 0.5 0.208 54.8 0.9 0.249 
 
 
CR = 1.6 
CR = 1.6 
(b)  
CR = 1.6 
CR = 1.6 
(a) 
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The polydispersity index (PDI) should also be mentioned. The PDI results from the 
cumulants fit to the autocorrelation function determined in the DLS instrument, and 
provides an indication about the size distribution of the particles in the sample. In general, 
systems with PDI smaller than 0.05 are very monodisperse, and above 0.7 are very 
polydisperse. PDI values between 0.05 and 0.7 display a moderate polydispersity. The 
PDI of both systems can be found in table 5. Although the PLL / ctDNA has an overall 
bigger size, its polydispersity is equivalent to the PLL-pDNA. The sample with higher PDI 
is that of CR = 0.5. This sample contains the least amount of polymer making the 
particles a little less uniform. The rest of the samples yielded a PDI between 0.1-0.2, 
which may be considered a monodispersed system.  
A study of the stability over time regarding PLL and pDNA was made. Figure 20 shows 
that polyplexes with high charge ratio have a tendency to maintain their size for at least 
3 weeks. This is likely due to the excess of PLL that is expected to reside at the surface 
of the polyplexes, conferring them colloidal stability by electrostatic repulsions. At low 
CR (CR < 2) polyplexes show significant differences but are able to remain below 200 
nm.  
These findings seem to be in agreement with other works. On a study regarding the gene 
delivery vectors for extended systemic circulation138, the system PLL (205k) / pDNA was 
studied at CR = 2 and at DNA concentration of 20 μg.mL-1. Particles with 84±2 nm in 
diameter with a PDI of 0.160 were obtained, which compares reasonably well with 67±1 
nm with PDI of 0.249 obtained here. In terms of zeta potential, they obtained a 
39.3±0.4mV, while 49.5±6.9mV was measured here. Also, in that work, cryo-TEM 
images of PLL-pDNA at CR = 2 were obtained, displaying particles with a distorted 
spherical and rod-like shapes. Given the similarities in size and shape with this study, 
the polyplexes PLL-pDNA described here are likely to have a similar structure. 
Fig. 20 - Study of stability of poly-L-lysine and pDNA polyplexes in water, upon preparation () and three weeks later (), as a 
function of charge ratio, and fixed DNA concentration (11.5 μg.mL-1). 
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Physiological ionic strength and pH effects on polyplex formation: the path matters 
 
When developing particles for biological applications, one has to consider the 
environment in which they will be used. In order to achieve conditions more closely 
related to physiological ones, we used a 20 mM Hepes buffer with pH 7.4 (similar to 
blood pH) and added NaCl to complete a total monovalent salt concentration of 150 mM 
(also similar to physiological ionic strength)139. As mentioned in section 3.1.2, two 
different experiments were performed. In the first experiment (path I), polyplexes are 
formed in water and the buffer is added only afterwards. In the second experiment (path 
II), polyplexes are formed in the presence of the buffer.  
Path I: In this first experiment, polyplexes were prepared by mixing PLL and pDNA in 
water, at fixed pDNA concentration of 11.5 μg.mL-1, in the same range of CR described 
previously. Then, buffer was added to the solution to achieve 150 mM ionic strength and 
pH 7.4. Figure 21 shows a comparison of the sizes and zeta potential of polyplexes in 
water and buffer. 
Upon addition of the buffer, an overall increase in the size is observed, but the profile 
remains similar to the studies made in water. A decrease in size is observed for bigger 
charge ratios (figure 21.a). From CR 1-2, an aggregation gap is obtained, grey area 
marked in the figure 21 plots, this gap coincides with the zeta potential inversion zone 
observed in water (figure 19.b). These changes in size are likely to result from the 
screening of the particles’ surface charge by the salt present in the buffer (this screening 
effect will be more evident in the study of the effect of intermediate ionic strength on 
polyplexes). This screening leads to a weakening in electrostatic repulsions which were 
important in providing colloidal stability to the particles, and this effect is likely to result in 
(a) (b) 
Fig. 21 - Study of the effect of buffer at pH7.4 and 150 mM NaCl on the stability of polyplexes (path I), at fixed DNA concentration 
of 11.5 μg.mL-1. (a) Size profile of polyplexes in buffer () and in water (); (b) zeta potential profile of polyplexes in buffer () 
and in water (). The macroscopic aggregation region is shown in grey. 
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aggregation. These observations are supported by the decrease in the magnitude of the 
zeta potential as shown in figure 21.b. In addition, some signs of macroscopic 
aggregation become visible in all the samples in less than one week, indicating that 
besides an increase in size, indeed these particles are colloidally less stable in this buffer 
than in water.  
Path II: In the second experiment on the effect of the buffer, PLL-pDNA  were already 
prepared in the presence of the buffer. Polyplexes were prepared by mixing PLL and 
pDNA in 20 mM HEPES and 150 mM ionic strength, at fixed pDNA concentration of 11.5 
μg.mL-1.  Figure 22 shows the results of DLS measurements and visual observations for 
the polyplexes prepared in buffer.  
 
As can be seen, there is a much larger aggregation gap (from CR 1-5), where 
macroscopic aggregation is visually observed. Simultaneously, the samples that did not 
show macroscopic aggregation showed a significant increase in size as compared to the 
sizes observed in path I (polyplexes prepared in water and buffer added later). Overall it 
seems evident that although the final composition is the same for samples in both path I 
and path II, the sizes of the polyplexes are very different. Since the major driving force 
for complexation between pDNA and PLL is the electrostatic interaction, which ultimately 
results in a large entropy gain due to the release of the sodium and bromide counter ions 
(from DNA and PLL, respectively), one can hypothesize that the higher ionic strength at 
the moment of complexation in path II makes complexation slightly less favorable. This 
may result in a slowing down of complexation, which like most nucleation processes, by 
being slower, can grow into larger particles. 
Fig. 22 - Study of the effect of buffer at pH7.4 and 150 mM NaCl on the formation of bioreducible polyplexes (path II), at fixed 
DNA concentration of 11.5 μg.mL-1. (a) Size profile of polyplexes in buffer () and in water (); (b) zeta potential profile of 
polyplexes in buffer () and in water ().The macroscopic aggregation region is shown in grey. 
(a) (b) 
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 Effect of intermediate ionic strength in PLL-pDNA polyplexes 
 
To gain further insight on the role of the ionic strength in the formation of polyplexes, we 
studied the effect of intermediate ionic strength in complexation. For these experiments, 
the procedure was the same as for the study of the effect of buffer, but varying the ionic 
strength. The tested ionic strengths were 20 mM, 30mM, 70mM, 100 mM and 150mM at 
pH 7.4. These buffers were tested for charge ratios, CR = 3, 5 and 7. CR = 10 was 
excluded because it uses a lot of reagent and the size results can be comparable to CR 
= 7.  
Figure 23 summarizes the results from the addition of buffer with variable ionic strength 
on polyplexes previously prepared in water (path I). Until 70 mM, the differences are very 
subtle, but become more significant at 100 mM and especially at 150 mM ionic strength. 
It is also evident that these effects are more striking at lower CR (CR = 3), which suggests 
that at CR 5 and 7 the polyplexes are more highly charged, making them colloidally more 
stable. Table 6 show the sizes obtained by DLS, and also the Debye screening length 
for each ionic strength. With increasing ionic strength, the screening length decreases, 
which means that the net electrostatic effect of polyelectrolytes in solution is weakened. 
To compare, in water, the Debye screening length is around 20 nm.    
  
Fig. 23 – Influence of the ionic strength on the size of polyplexes prepared in water (path I), at fixed DNA concentration of 11.5 μg.mL-
1 and pH 7.4. Polyplexes in water (), in 20 mM (), in 30 mM (▲), in 70 mM (▼), in 100 mM (♦), and in 150 mM  (►). 
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Table 6 - Size of polyplexes regarding the study of the effect of buffer at pH7.4 and ionic strength on the stability of polyplexes (path 
I), at fixed DNA concentration of 11.5 μg.mL-1. Debye screening length was calculated considering the ionic strength of the medium.  
 
Figure 24 summarizes the results on the effect of ionic strength on polyplexes prepared 
in buffer (path II). In this path, the differences between increasing ionic strengths are 
more visible. For the buffer with 30 mM ionic strength, the size of polyplexes with CR = 
3 and 5 is already significantly larger, and this trend keeps increasing with increasing 
ionic strength. At 150 mM, only semi stable particles at CR = 7 are observed. Table 7 
shows the sizes obtained by DLS, and also the Debye screening length for each ionic 
strength.    
Ionic 
Strength 
CR = 3 CR = 5 CR = 7 Screening 
Length 
I /mM 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm Size /nm Std /nm κ-1 /nm 
20 72.5 1.8 74.8 5.8 61.5 2.3 2.1 
30 78.1 5.5 74.2 7.9 74.8 2.6 1.8 
70 90.0 7.3 102.7 28.3 67.0 5.1 1.1 
100 139.4 23.1 111.7 3.1 91.9 8.2 1.0 
150 409.4 105.1 215.5 6.5 173.7 3.9 0.8 
Fig. 24 - Influence of the ionic strength on the size of polyplexes prepared in buffer (path II), at fixed DNA concentration of 11.5 
μg.mL-1 and pH 7.4. Polyplexes in water (), in 20 mM (), in 30 mM (▲), in 70 mM (▼), in 100 mM (♦), and in 150 mM  (►). 
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Table 7 - Size of polyplexes regarding the study of the effect of buffer at pH7.4 and ionic strength on the formation of polyplexes 
(path II), at fixed DNA concentration of 11.5 μg.mL-1. Debye screening length was calculated considering the ionic strength of the 
medium. 
Ionic 
Strength 
CR = 3 CR = 5 CR = 7 
Screening  
Length 
I /mM 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm Size /nm Std /nm κ-1 /nm 
20 76.5 1.7 73.3 7.4 68.2 3.7 2.1 
30 125.5 13.5 97.4 6.1 61.6 0.4 1.8 
70 155.5 21.3 139.6 5.6 151.5 3.3 1.1 
100 271.4 7.1 171.7 8.9 110.1 37.4 1.0 
150 aggr.  aggr.  279.2 17.8 0.8 
 
 
3.2.2 Bioreducible poly-L-lysine and plasmid DNA 
 
The bioreducible poly-L-lysine was obtained by oxidation of the respective monomers 
(CKKKKKC) by DMSO. This reaction allows little control over the extent of polymerization 
and hence, little control over the chain length. Thus, the polymer is expected to be 
significantly polydisperse.   
 
Preparation in water of bPLL-pDNA polyplexes 
  
For the bPLL and pDNA system in water, the size and zeta profiles can be observed in 
figure 25. The quantity of pDNA used in these studies is the same as for the PLL studies, 
so that the results from both studies are more readily comparable.  
The size profile can be observed in figure 25.a, and the zeta potential profile can be seen 
in figure 25.b. The peak observed in the PLL system has now shifted to CR = 2.1 with 
bPLL. This may be due to structural differences caused by the cysteines or to the 
presence of non-polymerized CK5C or impurities that do not contribute to complexation, 
but cause a systematic error in the weighing of the polymer. Despite this shift, the 
similarities between the PLL-pDNA and bPLL-pDNA systems are striking. Both 
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preparations have quite similar sizes, with the size observed for high CR being close to 
70 nm in the bPLL complexes. The same inversion of surface electric potential is also 
observed in both cases. Polyplexes with low CR (CR 0.5-1.7) have highly negative zeta 
potentials, around -50 mV, while high CR polyplexes (CR 2.5-10) have highly positive 
zeta potentials.  
 
 
 
 
 
 
 
 
 
 
 
 
The polydispersity index (PDI) results from the cumulants fit to the DLS data and gives 
an indication about the size polydispersity of the system. The PDI of bPLL-pDNA can be 
found in table 8. These indexes indicate a higher level of polydispersity when compared 
to the PLL-pDNA. This difference is likely to be associated with the bioreducible poly-L-
lysine and it is possible high level of polydispersity.  
We also investigated the colloidal stability of bPLL and pDNA polyplexes in water. Figure 
26 shows that polyplexes are able to maintain their size in water for at least 3 weeks, 
mainly due to high cationic repulsions. Polyplexes with CR = 2.1 and 2.5 were the only 
that aggregated.  
  
(a) 
(b) 
Fig. 25 – Comparison between polymers, bPLL ()  and PLL (), with plasmid DNA, in water with variation of charge ratio, at 
fixed DNA concentration (11.5 μg.mL-1). (a) Size of polyplexes against charge ratio; (b) zeta potential of polyplexes against charge 
ratio. 
CR = 2.1 
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bPLL-pDNA system 
CR Size /nm Std /nm PDI 
1 79.7 2.4 0.368 
1.5 72.1 2.6 0.228 
1.6 86.4 1.9 0.227 
1.7 94.8 3.9 0.257 
2 112.7 1.4 0.321 
2.1 500.1 11.2 0.351 
2.2 97.1 3.4 0.294 
2.5 85.4 1.0 0.331 
3 82.5 3.1 0.279 
5 74.0 3.4 0.331 
7 66.9 10.4 0.187 
10 75.1 2.0 0.250 
Table 8 – Size and polydispersity values obtained by DLS for bioreducible poly-L-lysine/pDNA systems, at fixed concentration 
(11.5 μg.mL-1).   
Fig. 26 - Study of the stability of bioreducible poly-L-lysine with pDNA polyplexes in water, upon preparation () and three 
weeks later ()  as a function of charge ratio, at fixed pDNA concentration (11.5 μg.mL-1). Aggregation zone showed in grey. 
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Physiological ionic strength and pH effects on bPLL-pDNA polyplexes 
 
We further investigated the effect of physiological ionic strength and pH on the 
complexation between bPLL with pDNA. The tests with 20 mM HEPES, 150 mM ionic 
strength at pH 7.4 made for the PLL-pDNA system were repeated for the bioreducible 
polymer, including the order of addition of the buffer. 
For the case of bioreducible polyplexes prepared in water, with buffer added after 
complexation (path I), it was observed little stability on physiological buffer. Results can 
be seen in Table 9. Aggregation was observed from basically every sample, except for 
CR = 1.  
For the case of preparation of polyplexes in buffer (path II), the results are similar to path 
I. Table 10 shows the size and zeta potential of those polyplexes. Aggregation occurs 
for all charge ratios, except CR = 1. Also, zeta potential indicates low surface electrical 
potential in a similar way to what was found for the PLL/pDNA system.  
 
 
Table 9 - Values of size and zeta potential acquired for the study of the effect of buffer at pH7.4 and 150 mM NaCl on the stability of 
bioreducible polyplexes (path I), at fixed DNA concentration of 11.5 μg.mL-1.  
 
 
  
 bPLL-pDNA in physiological buffer 
CR DH /nm PDI Std /nm ζ-potential /mV Std /mV 
1 160.6 0.779 13.0 -0.4 0.8 
1.7 
Aggregated 
-1.9 1.2 
2 -1.9 3.7 
2.1 -0.2 1.8 
2.2 -0.5 2.4 
3 7.0 8.7 
5 6.9 0.2 
7 4.6 1.8 
10 5.5 1.7 
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Table 10 - Values of size and zeta potential acquired for the study of the effect of buffer at pH 7.4 and 150 mM NaCl on the formation 
of bioreducible polyplexes (path II), at fixed DNA concentration of 11.5 μg.mL-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of intermediate ionic strength in bPLL-pDNA polyplexes 
 
To investigate the influence of the ionic strength on the bioreducible polyplexes, and to 
determine the maximum ionic strength in which polyplexes remain somewhat stable, we 
performed measurements at increasing ionic strengths (20 mM, 30 mM, 50 mM and 70 
mM) at pH 7.4. Here, owing to the smaller amount of bPLL available, the number of ionic 
strength concentrations investigated was reduced. These buffers were tested for charge 
ratios, CR = 3, 5 and 7. Figure 27 shows the results obtained for the case of bioreducible 
polyplexes prepared in water, with buffer added after complexation (path I), These 
bioreducible polyplexes show very little stability at higher ionic strengths. Whereas 
regular polyplexes are able remain colloidally stable in 150 mM, bioreducible polyplexes 
show macroscopic aggregation already at 50 mM. Table 11 shows the sizes obtained by 
DLS, and also the Debye screening length for each ionic strength. With increasing ionic 
strength, the screening length decreases, which means that the net electrostatic effect 
 bPLL-pDNA in physiological buffer 
CR DH /nm PDI Std /nm ζ-potential /mV Std /mV 
1 242.8 0.451 27.0 -3.1 1.7 
1.7 
Aggregated 
-1.3 1.5 
2 -1.8 0.3 
2.1 -1.4 1.9 
2.2 2.0 4.1 
3 0.9 0.6 
5 -0.6 0.6 
7 2.6 2.0 
10 2.3 1.0 
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of polyelectrolytes in solution is less predominant. To compare, in water, the Debye 
screening length is around 20 nm.          
Figure 28 shows the results obtained for the case of bioreducible polyplexes prepared in 
buffer (path II). Like in path I, the stability is very reduced, and above 30 mM ionic 
strength macroscopic aggregation is observed for all charge ratios. Table 12 shows the 
sizes obtained by DLS, and also the Debye screening length for each ionic strength.   
 
 
Table 11 - Size of bioreducible polyplexes regarding the study of the effect of buffer at pH 7.4 and ionic strength on the stability of 
polyplexes (path I), at fixed DNA concentration of 11.5 μg.mL-1. Debye screening length was calculated considering the ionic strength 
of the medium. 
 
 
Ionic 
Strength 
CR = 3 CR = 5 CR = 7 
Screening 
Length 
I /mM 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm κ-1 /nm 
20 300.0 20.8 104.7 9.3 88.3 2.3 2.1 
30 aggr.  274.5 7.9 202.9 0.6 1.8 
50 aggr.  aggr.  aggr.  1.1 
Fig. 27 - Size of bioreducible polyplexes regarding the study of the effect of buffer at pH7.4 and ionic strength on the stability of 
polyplexes (path I), at fixed DNA concentration of 11.5 μg.mL-1. Ionic strength ranging from 20-150 mM. Polyplexes in water (), 
in 20 mM (), in 30 mM (▲). 
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Table 12 - Size of bioreducible polyplexes regarding the study of the effect of buffer at pH7.4 and ionic strength on the formation of 
polyplexes (path II), at fixed DNA concentration of 11.5 μg.mL-1. Debye screening length was calculated considering the ionic strength 
of the medium. 
 
 
3.2.3 Glutathione test 
 
The main purpose of the bioreducible polymers is the ability to degrade when exposed 
to cellular cytosol, more specifically to glutathione (GSH) present in the cell matrix80-81, 
140. Here, to test the ability of the bioreducible polyplexes to degrade, we performed a 
series of experiments where glutathione is added.   
Ionic 
Strength 
CR = 3 CR = 5 CR = 7 Screening 
Length 
I /mM 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm 
Size 
/nm 
Std /nm κ-1 /nm 
20 aggr.  112.5 17.1 98 1.2 2.1 
30 aggr.  129.6 11.5 139.1 11.3 1.8 
50 aggr.  aggr.  aggr.  1.1 
Fig. 28 - Size of bioreducible polyplexes regarding the study of the effect of buffer at pH 7.4 and ionic strength on the formation of 
bioreducible polyplexes (path II), at fixed DNA concentration of 11.5 μg.mL-1. Polyplexes in water (), in 20 mM (), in 30 mM 
(▲). 
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Two GSH concentrations, 20 mM and 40 mM, were studied. These concentrations are 
believed to be the normal cell cytosol and the cancerous cell concentration, respectively. 
After GSH addition a waiting time of 1 hour. 
Polyplexes were prepared for charge ratios 3, 5, 7 and 10, and before GSH addition, 
DLS measurements were taken. Those results are shown in figure 29.a. The size profile 
is as seen before, small complexes which diameter decreases with increasing CR. Upon 
addition and incubation of GSH, the size profile was taken again. Results are shown in 
figure 29.b. Although one was expecting a decrease in size due to the bPLL degradation, 
the size of all samples increased drastically to the point where they fall out the size range 
of the equipment. They are between 10 000 – 30 000 nm, i.e. 10 – 30 μm. This difference 
displays that some surface destabilization occurred that led to the formation of big 
particles. This destabilization could be either by electrostatic screening or degradation of 
particle surface polymer50.      
In figure 30.a and 30.b, it is possible to see the difference in delay time from samples 
before and after glutathione, 20 mM and 40 mM, respectively. It is important to notice 
that after the addition of the GSH, the fitting becomes more complex, existing possibly 
more than one population.  
 
Additional tests using GSH were performed. Optimum GSH concentration, to observe 
gradual increase in size of polyplexes over time, was found to be 10 mM of glutathione 
for polyplexes with CR = 3. This experiment was also done on PLL-pDNA as a control. 
Figure 31.a show the study of the effect of glutathione over time. The point x = 0 refers 
to the measurement before addition of GSH.  The DLS measurements were taken with  
Fig. 29 - Study of the effect of glutathione in bioreducible polyplexes with variation of charge ratio, at fixed concentration (11.5 
μg.mL-1). (a) Size results before GSH addition, 20 mM  () and 40 mM (); (b) size results after GSH addition  incubating for 
1h, 20 mM  () and 40 mM (). 
(a) (b) 
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2 minutes of each other. Within 10 minutes of addition, the size has already increased 
around 4 times. It keeps increasing for that point on. The last measurement was made 4 
weeks after the addition, with no signs of any possible particle disassembly. On the other 
end, poly-L-lysine polyplexes are able to maintain their size throughout all time, see 
figure 31.b. The last measurement was also made 4 weeks after addition, at this time 
polyplexes were not stable anymore and had aggregated. 
 A study regarding vectors based on reducible polycations141 studied the bioreducibility 
of the system CK10C polymer (187k) / pDNA in 25 mM DTT – dithiothreitol. DTT is a 
reducing agent, similar to GSH. Bioreducible polyplexes at CR = 2 and DNA 
concentration of 20 μg.mL-1 suffered an increase in size, while non-reducible polyplexes 
- PLL-pDNA - remained stable. This finding agrees with the study described here. Cryo-
TEM images were taken of the before and after the addition of 25 mM DTT. Before the 
(b) 
3 days 
(a) 
  
3 days 4 weeks 
Fig. 31 - Study of the effect of 10 mM glutathione at pH 7.4 in bioreducible polyplexes with variation of charge ratio, at fixed 
concentration (11.5 μg.mL-1). x = 0 is the measurement before addition of GSH. (a) Bioreducible polyplexes, and (b) regular 
polyplexes. 
Fig. 30 - Normalized autocorrelation functions obtained from DLS measurements for the study of addition of GSH to bioreducible 
polyplexes at CR=5, and at fixed DNA concentration (11.5 μg.mL-1). (a) Study of the effect of 20 mM GSH. Measurements made 
before GSH addition (+), (), (), and after incubation for 1h at room temperature (), (), (*); (b) Study of the effect of 20 mM 
GSH. Measurements made before GSH addition (+), (), (), and after incubation for 1h at room temperature (), (), (*). 
(a) (b) 
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addition, polyplexes were very discrete particles with diameters ranging from 50-200 nm 
with quasi-spherical shape, however treatment with DTT caused extensive aggregation 
of the sample. 
 
Polyplex preparation with CK5C  
 
Apart from using regular poly-L-lysine as a glutathione control, samples containing 
monomeric bioreducible poly-L-lysine were prepared to be tested in 10 mM of 
glutathione. For this purpose, we mixed pDNA with CK5C (i.e. monomeric bPLL) at a 
fixed charge ratio of 3, and fixed DNA concentration (11.5 μg.mL-1) to check whether 
polyplexes would form with the short peptide of 5 positive charges. Table 13 shows the 
size results obtained for this experiment. 
 
Table 13 – Study of the addition of GSH to polyplexes prepared with monomeric bPLL / pDNA, at CR = 3, and at fixed DNA  
CR = 3  Size /nm Std /nm 
Without GSH 8326.5 75.2 
After GSH 
Time Size /nm Std /nm 
3 minutes  14128.6 4671.1 
3 days 36264.7 14486.1 
4 weeks 55756.0 14747.1 
.  
Upon addition of the CK5C to the pDNA solution, a visible white precipitate formed in the 
solution, suggesting that large polyplexes form, although without colloidal stability. Even 
though there is a large excess of positive charges (like in the case of PLL and bPLL at 
CR=3), perhaps due to the much smaller size of the monomers it becomes more difficult 
to overcharge the polyplexes (i.e. the smaller peptides make it very easy to find the exact 
match for charge neutrality) which leads to very favourable aggregation of CK5C with 
pDNA but without a stop mechanism caused by excess charge repulsion. However, other 
studies show successful preparation of polyplexes using polymer monomers21, 142. This 
also provides a clue to the aggregation of polyplexes followed by addition of GSH: most 
likely, the excess of bPLL overcharge on the surface of polyplexes is cleaved away, 
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leading to the loss of positive charge on the surface, and consequent loss of colloidal 
stability.  
GSH was also added to these CK5C-pDNA complexes, to a final concentration of 10 mM. 
A continuously increase in size after the addition was observed, but it is likely that the 
size would increase with aging independently of GSH addition.  
Overall this experiment demonstrates that even though the bPLL degrades (at least 
partially) in reducing media, this degradation by itself is not enough to disassemble 
polyplexes in our in vitro conditions (physiological pH and ionic strength). This by itself 
does not mean that bioreducible polyplexes will be inefficient in vivo. As interactions in 
vivo are more difficult to assess, transfection efficiency experiments are required. It is 
important to point out that in a similar study using bioreducible multivalent lipids instead 
of bPLL, the transfection efficiency did not improve when compared to non-bioreducible 
analogue lipids, but the cytotoxicity of the vector was significantly reduced, which is also 
an important aspect143. Furthermore, in a continuation of that study16, small-angle x-ray 
scattering (SAXS) was able to elucidate that after the bioreducible multivalent cationic 
lipid is cleaved, the initial structures containing the DNA were destabilized, but a new 
structure with the DNA condensed by the cleaved multivalent headgroups as formed, 
indicating that the DNA release is more complex than initially assumed. 
In a recent study using a bioreducible poly-L-lysine block copolymer with plasmid DNA, 
a better transfection efficiency was achieved when compared to polyplexes from 
nonbioreducible block copolymers analogues. Also, these bioreducible polyplexes 
showed lower cytotoxicity144.  In another study, bioreducible PEI polyplexes were shown 
to have lower cytotoxicity as well as higher transfection efficiency when compared with 
low molecular and high molecular nonbioreducible analogues145. The same result 
regarding improved transfection efficiency when using bioreducible polyplexes may be 
found elsewhere50, 146.  
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3.3.3 Microfluidics 
 
3.3.1 Microfluidic assembly of Poly-L-lysine and plasmid DNA polyplexes 
 
Microfluidics constitutes a promising platform for the controlled self-assembly of more 
complex materials, including liposomes147-149, multiple emulsions150-151 and polyplexes152-
155. One of the goals of this project was to use microfluidic-based methods to control the 
assembly of bioreducible polyplexes and achieve a better control over their size and 
polydispersity.  
To perform these experiments, we started by using a simple 2D cross-shaped 
microfluidic hydrodynamic focusing (MF) device (figure 9.a), made of 
polydimethylsiloxane (PDMS) with microchannels 200 μm width and 50 μm depth. The 
device consists of three inlets and one outlet. The side inlets are connected to two 
syringes containing PLL, while the central inlet is connected to the pDNA solution. The 
syringes are mounted on two syringe pumps that control the flow rate of each syringe 
independently: Q2, which is the flow rate of the central stream (pDNA) is controlled by 
one syringe pump, whereas Q1 and Q3, which are the flow rates of the side streams 
(PLL), are controlled by the other syringe pump. This allows to fine tune the flow rate 
ratio (QR) of the PLL to pDNA streams.  The pDNA solution is hydrodynamically focused 
by the PLL streams from the side channels into a narrowly focused stream. For the flow 
visualization, the MF device was mounted on an inverted microscope stage NIKON 
Eclipse Ti with a Plain Fluor 20x/0.45 objective. The focused stream containing DNA and 
the side streams containing PLL have no optical contrast and therefore are not 
distinguishable under normal light. As such, fluorescein dye (11.7 μM) was added to the 
DNA solution to color the focused stream, and allow a suitable monitoring of the flow 
within the device. A range of flow rates were studied to assess their influence in the 
formation of polyplexes (table 2), and in an attempt to find suitable conditions for optimal 
polyplex formation, i.e. conditions that allow a control over the size and polydispersity. 
The microfluidic-produced polyplexes were characterized by DLS. 
For MF, the charge ratio was fixed at CR=7. The pGL3 and PLL solutions were injected 
at individual flow rates to satisfy the conditions QR=2, 10, 30 and 50, and QT = 11 and 55 
μL.min-1 (table 3). Fluorescence images of the hydrodynamic focusing can be found in 
figure 32. By analyzing fluorescence images an approximate measurement of the central 
stream width (wf) can be obtained. As mentioned in section 1.4.3, wf is not constant 
through the depth of the channel, but rather has a concave shape because of the slower 
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fluid velocity near the walls. Hence, these measurements are likely to be slightly 
overestimated, especially at high QR (i.e. narrow widths), because the projection imaged 
in the microscope is likely to capture the larger width of the stream. From equation 10, it 
is also possible to roughly estimate the width of the focused streams. Eq. 10 is suitable 
for 2D geometries like the one used here, but is limited by the assumption that wf is 
constant throughout the channel depth, which is not true like mentioned above. With 
these limitations in mind, both in the measured and estimated widths, the discrepancies 
are expected, and these values should be taken as qualitative indicators of 
hydrodynamic flow focusing (table 14). As expected, for higher QR, the width of the 
central stream decreases, allowing faster mixing by diffusion99.  
 
Table 14 - Comparison between the measured and estimated widths of the central stream (wf) at fixed QT = 11 μL.min
-1. 
  QT=11 μL.min-1  QT=55 μL.min-1   
QR  Q2 Q1 + Q3 wf  Q2 Q1 + Q3 wf  wf (estimated) 
2  3.667 7.334 55  18.33 36.67 53  67 
10  1.000 10.00 17  5.000 50.00 26  18 
30  0.355 10.65 14  1.774 53.23 24  6 
50  0.216 10.78 10  1.078 53.92 18  4 
 
For the first experiment with MF preparation, all samples were prepared on the same 
device. Between sample preparations, channels were cleaned with 1 M NaCl, DI water 
and finally F127 pluronic (commonly used to make the PDMS hydrophilic and avoid 
particle absorption). To assess the size of the polyplexes prepared by MF, DLS 
measurements were made at 173º and 90º. Results are shown in table 15. In figure 33.a 
and 33.b are shown the diameters of the prepared polyplexes measured at 173º for QT 
= 11 μL.min-1 and QT = 55 μL.min-1, respectively. 
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Table 15 – Assessment of size of polyplexes prepared by MF at varying flow rates, and at fixed CR = 7. Measurements made at 173º 
and 90º. Also, size results applying a matlab methodology using the output given at 173º and 90º. All preparations were made in the 
same microchip.    
 
 173º 90º Matlab 
QR QT DH /nm Std /nm PDI DH /nm Std /nm PDI DH /nm 
2 11 167.9 13.3 0.429 295.7 144.3 0.352 182.3 
10 11 404.5 35.9 4.507 261.7 100.4 0.409 320.8 
30 11 272.3 26.8 0.522 617.5 74.9 0.359 132.6 
50 11 314.5 14.2 1.044 3850.4 3263.6 1.208 415.1 
2 55 198.2 4.9 0.434 241 193.4 0.339 178.5 
10 55 150.7 3.2 0.473 251.9 65.5 0.476 264.3 
30 55 166.5 9.6 0.494 315.9 58.8 0.366 174.2 
50 55 286.1 19.3 0.361 947.8 114.2 0.493 140.2 
(a) (b) 
(c) (d) 
Fig. 32 – Hydrodynamic focusing of a pDNA solution containing fluorescein (11.7 μM) by PLL solution coming from the sides. The 
polymer concentrations and flow conditions are such that CR is fixed at 7. (a) QR = 2 and QT = 11 μL.min
-1 (b) QR = 10 and QT = 11 
μL.min-1 (c) QR = 30 and QT = 11 μL.min
-1 (d) QR = 50 and QT = 11 μL.min
-1 
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Although the expectation was that with the enhanced fluid manipulation and mixing 
control given my MF, one could produce monodisperse polyplexes and control their size, 
the results showed the opposite. For CR=7, polyplexes became more polydisperse, and 
furthermore, the size dependence with QR was erratic (table 15 and figure 33). 
Unexpectedly, repeatability was also very low. This hinted at problems with the device. 
Indeed, during flow, we noticed that some macroscopic aggregates would form at the 
interface of pDNA and PLL, in the top and bottom microchannel walls. These aggregates 
would get stuck to the walls, and rarely would come off, not even with a 1 M NaCl solution 
pumped through the channels. The aggregates can be seen in figure 34.a and 34.b. We 
hypothesize that this uncontrolled aggregation at the walls can act as a source of larger 
particles that spoil a hypothetical narrower size distribution that we were expecting to 
obtain.  
 
  
(a) 
2 10 30 50 
(b) 
2 10 30 50 
Fig. 33 - Microfluidic-assisted preparation of poly-L-lysine polyplexes at fixed CR = 7. DLS measurements obtained at 173º. All 
preparations were made in the same microchip. (a) Diameter with varying flow rate ratio at fixed total flow rate (QT = 11 μL.min-1 ); 
(b) Diameter with varying flow rate ratio at fixed total flow rate (QT = 55 μL.min-1 ). 
Fig. 34 – Imagens of aggregation occurred during MF preparation of polyplexes. (a) Aggregates form during flow at QR = 2 and QT = 
11 μL.min-1 (b) Aggregates adhered to the wall after flow at QR = 10 and QT = 11 μL.min
-1 
(a) (b) 
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Because in the first experiment only one device was used for all the different flow 
conditions, we hypothesized that the surface aggregation could have formed at QR=2, 
which was the first tested flow rate ratio, and then contaminated all the subsequent 
conditions. As such, a second experiment was attempted by preparing each QR on a 
different device. This way one can avoid the influence of the previous aggregation on the 
new preparation. PDMS replicas were made from the same silicon master. All solutions 
and flow rates were kept the same. Results are shown in table 16. 
 
Table 16 - Assessment of size of polyplexes prepared by MF at varying flow rates, and at fixed CR = 7. Measurements made at 173º 
and 90º. Also, size results applying a matlab methodology using the output given at 173º and 90º. All preparations were made in the 
same microchip.    
 
 
Again, for this second experiment, different sizes were obtained for each QR with no 
visible tendency. The level of polydispersity was also equally high. Furthermore, 
macroscopic aggregates in the channel walls were again observed for all the flow 
conditions, indicating that this problem is independent of the flow conditions for this 
channel geometry, and likely to be the source of the erratic results. Such behavior was 
likely caused by the very low fluid velocity expected close to the walls114 (Poiseuille flow), 
which might facilitate the polymers (either condensed or non-condensed) sticking in an 
almost irreversible way to the channel walls. This occurred even though the PDMS 
 173º 90º Matlab 
QR QT DH /nm Std /nm PDI DH /nm Std /nm PDI DH /nm 
2 11 1076 248.6 0.578 213.1 0.7 0.344 327.9 
10 11 152.1 22.8 0.590 252.4 13.7 0.408 187.5 
30 11 364.5 8.1 0.709 1121.8 662.5 0.703 404.1 
50 11 345.3 7.2 0.892 1644.3 1091.1 0.629 392.2 
2 55 199.8 19.6 0.880 183.5 18.7 0.355 213.8 
10 55 944.4 288.2 0.546 935.7 386.5 0.443 1038 
30 55 470.9 208.3 1.898 894.5 75.1 0.472 344.7 
50 55 326 10.4 1.000 1172.5 696.1 0.639 371.3 
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channels were coated with F127 As an improvement to the future, we will develop a 3D 
flow focusing microfluidic device to avoid contact of PLL and pDNA with the walls156.  
These results were unexpected, especially bearing in mind that there are some 
successful cases already described in the literature, even for a simple 2D geometry like 
the one used here. Successful preparation of polyplexes by microfluidics using PEI – 
polyethylenimine – and  pDNA – pGL3 – using  a 2D hydrodynamic focusing has been 
described157. The preparation was made on a device made of PMMA, with microchannel 
width of 254 μm and depth of 70 μm, at QR = 10 and QT = 110 μL.min-1. The fact that the 
authors were able to produce polyplex smaller polyplexes with a more homogeneous 
size distribution can be related with a different material used to fabricate the device, or 
with the use of PEI instead of PLL.  
Recently, droplet microfluidics were used successfully to prepare polyplexes of pDNA 
(pGL3) and a poly(amidoamine), reporting a significant improvement compared to bulk 
preparation154. The confinement of the oppositely charged polyelectrolytes within 
droplets allowed a more controlled aggregation process, with each droplet acting as a 
microreactor. This allowed an improvement of size and polydispersity, although a 
tailoring of size was not mentioned (BM: d = 165.8±21 nm PDI = 0.342; MF: d = 
100.8±13.3 nm, PDI = 0.152).  
Recently, an ingenious experimental setup was described using relatively cheap 
commercial parts like a 23G needle, tee union tube fittings, and 3 mm inner diameter 
tubing, to create a 3D turbulent flow-focusing device155. The dimensions of the tubing 
(which act as the channels) are 3 mm so this is not a real microfluidic device, and indeed 
the flow conditions favor more turbulent regimes. Yet, the turbulent flow proved very 
useful for rapid and controlled mixing, which allowed the preparation of polyplexes of 
poly(2-hydroxyprpyleneimine) with pDNA. These polyplexes showed smaller size, slower 
aggregation rate, and higher transfection efficiency, while exhibiting reduced cytotoxicity 
compared to those prepared by bulk mixing. Also, this method proved reproducible for 
synthesizing these complexes. Importantly, the size of the particles was controlled (in 
this case decreased) by increasing the total flow rate (QT). Another especially attractive 
feature of this setup was the 3D focusing which helped avoid the polymers entering in 
contact with the tube walls. We expect that the next iteration of our device, including 3D 
focusing can avoid polymer aggregation to the walls, while adding additional control over 
particle synthesis owing to the improved flow control at low Reynolds numbers.  
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 3.4 Overview  
 
This project started with the study of complexation of calf thymus with poly-L-lysine, in a 
range of charge ratios, which resulted in very stable complexes, with charge 
neutralization around CR = 1.6. Polyplexes with high polymer content (high CR) have 
smaller sizes and high zeta potentials (>30 mV). When the type of DNA was changed to 
plasmid DNA, which is significantly smaller and monodisperse, the overall particle size 
dropped to half. This shows that PLL is able to compact pDNA into smaller structures. 
Nevertheless, size and zeta profiles were very similar to those of bPLL-pDNA. In 
conclusion, the interaction of DNA with PLL showed three regimes in the formation of 
polyplexes: (a) at low CR DNA-PLL polyplexes and partially condensed DNA chains 
coexist; (b) for CR close to neutrality, a coacervate forms with near-zero charge (ζ ~ 0); 
and (c) at high CR, positively charged polyplexes are formed with dH values of 60 to 80 
nm (figure 35). Cryo-TEM images of polyplexes prepared with similar pDNA and PLL at 
CR = 2 showed spherical and rod-like particle shape138.  
We have also observed the impact of DNA concentration on polyplex size. The 
experiment was made at fixed charge ratio. Larger particles were observed upon 
increasing DNA concentration. For the bPLL-pDNA system, the size profile showed 
similar sizes to those obtained for PLL polyplexes, except with a slight shift of particle 
charge neutralization (CR = 2.1). This may be due to structural differences caused by 
the disulfide bonds, or impurities resulting from the polymerization of the peptide. Zeta 
potential profile follows the trend observed for PLL / DNA and also seen in literature136.  
Fig. 35 – Representation of the model for the interaction of DNA / Polymer in aqueous solution, at increasing charge ratio136. 
 
When studying the effect of quasi-physiological buffer (20 mM HEPES, pH 7.4, 150 mM 
ionic strength), the order in which the buffer was added was taken into consideration. 
The PLL-pDNA system showed much higher stability to buffer at high CR. When adding 
the buffer after the formation of PLL polyplexes in water (path I), a window of aggregation 
was observed from CR 1-2. Conversely, when the formation of polyplexes was made in 
DNA 
Polymer 
+ Polymer + Polymer 
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aggregation 
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buffer (path II), the aggregation window increased to CR 1-5. In the latter case, the gain 
of entropy is lessened by the presence of excess ions in solution and this slows the 
process of nucleation, leading to bigger complexes. Further, the presence of salt also 
reduced electrostatic repulsions, making polyplexes less stable.  Nevertheless, an 
increase of particle size was observed. For the bPLL system, the effect of buffer was 
more evident. In both experiments aggregation was observed to all CR, except CR = 1. 
Perhaps the uncondensed pDNA present was able to stabilize particles.  
A study involving buffer (20 mM HEPES, pH 7.4) and varying ionic strength (20, 30, 70, 
100 and 150 mM) was performed for both PLL and bPLL systems to assess the effect of 
these parameters on polyplex stability and complexation. We observed an increase in 
the size of particles prepared at CR = 3, 5 and 7. For PLL-pDNA, when adding the buffer 
after polyplex formation in water (path I), polyplexes were not significantly affected until 
150 mM ionic strength was reached, whereas for polyplexes formed in buffer (path II), 
30 mM was enough to increase their size. Yet, polyplexes formed in up to 100 mM. For 
the bioreducible polyplexes, less stability was found. Polyplexes were able to remain 
stable or to form in buffer in an ionic strength up to 30 mM (paths I and II). 
Microfluidic preparation of polyplexes containing poly-L-lysine and plasmid DNA was 
performed. A 3-inlet 2D cross hydrodynamic focusing device was used. The polyplexes 
were prepared at fixed CR = 7, at different flow rate ratios, and at different total flow 
rates. Polyplexes were able to form using this device, but an erratic and non-reproducible 
behavior was observed. This is most likely due to significant aggregation of condensed 
and non-condensed polymers to the microchannel surface, indicating that the device 
needs to be optimized to avoid contact of the polyplexes with the walls (e.g. by using a 
3D flow focusing geometry).  
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4. Conclusion and Future Prospects  
 
The structural analysis of polyplexes carried out in this work are relevant for the 
development of more efficient polymer-based gene delivery systems, which rely on the 
molecular properties of the complexing agent. 
In this thesis, we were able to prepare and synthesize bioreducible poly-L-lysine and 
plasmid DNA. We successfully characterized the size, polydispersity and zeta potential 
of PLL-ctDNA, PLL-pDNA and bPLL-pDNA systems, in water and in a variety of buffers 
with different ionic strengths. 
We found that the type of DNA used to prepare polyplexes greatly affected the size of 
the final complexes. Polyplexes containing ctDNA were much larger than those 
containing pDNA. This trend may be originating from the different structures of each type 
of DNA. Both systems containing plasmid DNA had similar structural properties when 
prepared in water, while in the presence of buffer these properties differed significantly.  
We have demonstrated that the microfluidic hydrodynamic focusing method can 
condense plasmid DNA by PLL, but aggregation is due to happen inside the channel. 
Therefore, the microfluidic technique applied to this system still needs refining and 
optimization to achieve better control of particle size and stability (e.g. by using a 3D flow 
focusing geometry), allowing for further characterization and transfection studies. 
As concerning future prospects, further structural studies of small-angle X-ray scattering, 
fluorescence cross-correlation spectroscopy and cryo-TEM will be required to gain 
further insight on the interactions between polymer and DNA, and also on the effect of 
glutathione on bioreducible polyplexes. Optimization of the microfluidics technique 
applied to this system will be mandatory. Finally, transfection studies will be required to 
obtain structure-efficiency relationships. 
. 
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Appendix I 
 
Plasmid preparation 
 
Materials and reagents 
Granulated tryptone, granulated yeast extract and powder agar were acquired at Fisher 
Scientific. JM109 competent cells (E. coli), high efficiency, were purchased at Promega 
(cat. L2001). Plasmid DNA (pGL3 control vector) was purchased at Promega (cat. 
E1741). NaOH powder (99.99%), Tris-Cl powder (99.8%), isopropanol (99.8%), ethanol 
(99.8%) were purchased at Sigma. Giga Prep plasmid purification kit was purchased at 
Qiagen. The final pDNA solution concentration was acquired by NanoDrop 2000c 
spectrophotometer. 
 
Preparing Lysogeny Broth Media 
 
Materials:  
1. Tryptone 
2. Yeast Extract 
3. NaCl 
4. 2L flask 
5. 5M NaOH 
 
Procedure: 
To a Flask of volume 2L, add 5 g of tryptone, 2.5 g of yeast extract and 5 g of NaCl. Add 
500 mL of pure water and dissolve by magnetic stirring. Adjust the pH to 7.5 with 5M 
NaOH (typically 300 µL). Remove the magnetic bar. Cover the Flask with aluminum foil 
and autoclave. When finished, remove and allow to cool, but always keep covered with 
AL foil. This solution can be stored at 4°C. 
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Making LB Ampicillin Selection Plates 
 
Materials:  
1. Tryptone 
2. Yeast Extract 
3. NaCl 
4. Granulated Agar 
5. 2L Flask 
6. 5M NaOH 
7. Ampicillin 
 
Procedure: 
To a Flask of volume 2L, add 5 g of tryptone, 2.5 g of yeast extract and 5 g of NaCl. Add 
500 mL of pure water and dissolve by magnetic stirring. Adjust the pH to 7.5 with 5M 
NaOH (typically 300 µL). Add 7.5 g of granulated agar to the mixture and stir until partial 
dissolution. Remove the magnetic bar. Cover the Flask with aluminum foil and autoclave. 
When finished, remove and allow to cool. Sterilize hood surface with a UV cycle. Open 
a bag of sterile 3’’ empty plates and place them on stacks of 10. The 500 mL mixture will 
allow the preparation of 10-15 plates. When the mixture is cooled down enough, add 1 
mL of Ampicillin 50 mg.mL-1. Pour the LB agar into a sterile 500 mL beaker for easier 
transfer onto the plates. Fill the plates until half-full then allow them to set for 1 hour. 
Place lid on the plates and flip upside down to prevent condensation. Put the plates, 
upside down, inside the bag and store them at 4°C. 
 
Transforming Competent Bacteria Cells 
 
Materials: 
1. JM109 Cells 
2. LB Media 
3. LB Selection Plates  
4. Cryo-Safe 
5. ThermoMixer® 
6. 1.5 mL Eppendorf tubes 
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7. Sterile Cell Spreader 
8. Incubating Orbital Shaker 
 
Procedure: 
Remove cells form -79ºC and let them thaw on the Cryo-Safe. After mixing gently, aliquot 
25 µL of cells into a chilled, 1.5 mL Eppendorf tube. Add 0.500 µL of plasmid DNA 0.25 
mg.mL-1. Gently swirl tube on ice for a few seconds to mix by finger flicking tube. Then 
incubate tube on cryo-tablet for 30 minutes. Heat shock tube by placing in the 
ThermoMixer® at 42ºC for 45 seconds without shaking. Replace tube on ice for 2-5 
minutes. Add 500 µL of chilled LB media. Gently shake and incubate tube by placing in 
the ThermoMixer at 300 rpm for 90 minutes at 37ºC. After incubation, centrifuge 
Eppendorf tubes at 12000 rpm for 30 seconds to pellet the bacteria. Pour off most of the 
supernatant but leave behind around 120 µL. Resuspend bacteria by pipetting up and 
down. Spread 10 µL of bacteria solution on LB selection plates with a sterile cell 
spreader. Place the plate upside down in the 37ºC Orbital Shaker. Incubate overnight 
and remove to fridge (4ºC). The growth of cell colonies should be noticeable. 
 
Growing up Bacteria Cultures 
 
Material: 
1. LB media with ampicillin 
2. Cultures grown on selection plates 
3. 5x 2L flasks 
4. 50 mL Centrifuge Tubes 
5. Centrifuge 
6. 15 mL Falcon Tube 
7. Incubating Orbital Shaker 
8. Qiagen Giga Kit 
 
Procedure:  
Pick a colony from the selective plate by using a sterile 200 µL pipette tip and just scoop 
up a colony. Then place the whole tip right into a 10mL Falcon tube containing 5 mL of 
LB. Grow at 37ºC for 8 hours at 275 rpm. Dilute the grown culture 1/500 into a larger 
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volume of selective LB medium. Use a flask of at least 4 times the volume of culture to 
ensure sufficient aeration. For the Qiagen Giga kit, 2.5 L of culture are needed. So, five 
2L Flask filled with 500 mL of selective LB. Aliquot 1 mL from the grown culture into each 
Flask. Grow the culture at 37ºC with vigorous shaking for 12/16h. NOTE: The growth of 
12/16h corresponds to the transition from logarithmic into stationary growth phase, when 
the cell density is high and the RNA content is low.  Collect the bacteria by centrifugation 
at 6000 rpm for 15 minutes at 4ºC. Make sure all centrifuge tubes have the same weight. 
Remove all supernatant. 
 
Plasmid Prep – Qiagen Giga Kit 
 
Materials: 
1. Centrifuge 
2. 50 mL Centrifuge Tubes 
3. 1L flask 
4. Isopropanol 
5. 70% Ethanol 
6. 10 mL of 10 mM Tris-Cl, pH=8.5 buffer solution 
 
All the buffers and separation column are provided by the Qiagen Giga Kit.  
 
Procedure: 
Harvest bacterial overnight culture by centrifuging at 6,000 rpm for 15 minutes at 4ºC. 
Try to re-use the 50mL tubes to reduce the number of pellets obtained. To a clean 1L 
flask, pour the bacteria pellets and resuspend them in 125 mL of Buffer P1. Add 125 mL 
of Buffer P2, mix thoroughly by inverting 4-6 times, and incubate at room temperature 
for 5-10 minutes. Add 31.25 ml of prechilled Buffer P3, mix thoroughly by vigorously 
inverting 4-6 times, and incubate on ice for 30 minutes. Centrifuge at 20,000 rpm for 30 
minutes at 4ºC. While centrifuging, calibrate the separation column with 75 mL of Buffer 
QBT. Then, apply the supernatant obtained to the column and wash it with 600 mL of 
Buffer QC. Elute DNA with 100 mL of Buffer QF into a clean vessel. Precipitate DNA by 
adding 70 mL room-temperature isopropanol and mix. Centrifuge at 15,000 rpm for 30 
minutes at 4ºC. Carefully decant the supernatant. Wash the DNA pellet with 10 mL room-
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temperature 70% ethanol, centrifuge at 15,000 rpm for 10 minutes. Carefully decant 
supernatant without disturbing the pellet. Finally, air-dry pellet for 10-20 minutes and 
redissolve DNA in a suitable volume of 10mM Tris-Cl, pH=8.5.  
It was possible to obtain 19.92 mg of pDNA pGL3. Value obtained by using NanoDrop™.       
